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 Abstract 
 
	 3 
One of the most relevant altered pathways in cancer is the DNA Damage 
Response (DDR), a well-coordinated network of signalling cascades that cells have 
developed during evolution in order to maintain genomic integrity. These pathways are 
activated when genomic material is damaged with the aim of transmit the damage 
signals to effector proteins, and induce cellular responses including cell cycle arrest, 
activation of DNA repair pathways, and cell death; thus preventing tumorigenesis. 
CHK2 and DYRK2 are key downstream kinases of the DDR, involved mainly in the 
regulation of cell cycle and DNA repair. The identification of new substrates for these 
kinases will delve into knowledge of their functions within the DDR, which leads to 
tumor development and progression when deregulated.  
In the present work we demonstrate how CHK2 presents the ability to 
phosphorylate the E3 Ubiquitin ligase SIAH2, affecting its activity on certain substrates. 
Additionally, SIAH2 regulates CHK2 basal turnover through ubiquitination and 
proteasomal degradation. In response to DNA damage, the interaction between both 
proteins is disrupted, which favors CHK2 stabilization. This new CHK2 regulation 
mechanism has an influence on cell cycle progression and on the ability of hypoxia to 
alter DDR pathway in cancer cells, since resistance to apoptosis induced by genotoxic 
agents in cells subjected to hypoxia could be partly explained by the mutual regulation 
between CHK2 and SIAH2. We also describe the capacity of DYRK2 to modulate the 
turnover of the checkpoint phosphatase CDC25A through an ubiquitin/proteasome and 
DYRK2 kinase activity dependent process. DYRK2 directly phosphorylates CDC25A in 
vitro, although DSG or KEN motifs are not involved in the CDC25A degradation by the 
proteasome mediated by DYRK2. Different stimuli, such as DNA damage or serum 
starvation, result in an inverse correlation of DYRK2 and CDC25A expression, which is 
also observed at endogenous levels in human lung cancer cell lines and human lung 
cancer tissues. 
Taken together, our findings report new substrates (SIAH2 and CDC25A) for 
two relevant kinases involved in the DDR pathway (CHK2 and DYRK2), helping to 
elucidate the molecular mechanisms through which this pathway operates. These data 
certainly help to improve the understanding of the regulation processes of these 
relevant kinases and will extend the knowledge about the molecular biology of cancer 
as well as provide new therapeutic opportunities for cancer treatment. 
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5-FU 5-Fluorouracil  
ADR Adryamicine 
ATM Ataxia telangiectasia mutated 
ATR Ataxia telangiectasia and Rad3 related 
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3.1. DNA Damage Response  
 
The search for new therapeutic targets and strategies is crucial in cancer 
research, not only for the development of new drugs, but also for use as prognostic 
markers which have become an important tool in cancer treatment. To achieve this aim, 
key molecular cell components that could be altered in carcinogenesis had been 
studied deeply over the last decade.  
 
One of the most relevant altered pathways in cancer is the DNA Damage 
Response (DDR), a well-coordinated network of signalling cascades that cells have 
developed during evolution in order to maintain genomic integrity. These pathways are 
activated when genomic material is damaged as a consequence of exposition to 
deleterious endogenous and environmental genotoxic agents, as well as the intrinsic 
chemical instability of the DNA molecule itself!(Hanawalt, 2015), with the aim of transmit 
the damage signals to effector proteins, and induce cellular responses including cell 
cycle arrest, activation of DNA repair pathways, and cell death (Ciccia & Elledge, 2010). 
When the DNA-damaging agents cause chromosomal instability in essential ‘driver’ 
genes, the cell behavior can be altered, conferring a selective advantage and driving 
the development of cancer. Notably, it also can determine the response to therapy of 
the tumor (Lord & Ashworth, 2012). 
 
3.1.1. Mechanism of DNA Damage Response 
 
Endogenous DNA damage is caused by reactive oxygen species (ROS) 
generated spontaneously during DNA metabolism, especially those arising from the 
process of oxidative deamination and from replication errors (they can be due to DNA 
bases interconversion, dNTP misincorporation, loss of DNA bases or modification of 
DNA bases by alkylation). Environmental DNA damage can be produced by physical or 
chemical sources. Examples of physical genotoxic agents are ionizing radiation (IR), 
ultraviolet (UV) light and certain plant toxins. Chemical agents are those used in cancer 
chemotherapy (human-made mutagenic chemicals, especially aromatic compounds), 
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without forgetting the smoke derived from cigarettes (Ciccia & Elledge, 2010; Tian et al., 
2015). 
 
These DNA-damaging agents can induce different types of DNA lesions 
including modification of bases, intrastrand or interstrand crosslinks (ICL), DNA–protein 
crosslinks, single-strand breaks (SSB) and double-strand breaks (DSB). Each type of 
DNA damage is recognized and processed by proteins involved in the DDR pathways, 
that can either work independently or coordinately to repair the lesions (Hosoya & 
Miyagawa, 2014). In any case, most of them encompass a similar set of tightly 
coordinated processes: DNA damage detection, DNA repair factors recruitment to the 
onset of the lesion and the final restore of the damage!(Lord & Ashworth, 2012). 
 
Under normal physiological conditions, there are seven major mechanisms 
entrusted of restoring the diverse types of DNA damage generated: base excision 
repair (BER), nucleotide excision repair (NER), homologous recombination (HR), non-
homologous end joining (NHEJ), Mismatch repair (MMR), activation of the Fanconi 
anemia (FA) pathway and translesion DNA synthesis (TLS). BER proteins repair most 
of the DNA subtle changes, such as oxidative lesions, alkylation products and SSBs. 
Poly (ADP-ribose) polymerase (PARP-1), XRCC1, DNA ligase IIIa, and apurinic ⁄ 
apyrimidinic endonuclease (APE1) are examples of BER proteins! (Dianov & Hubscher, 
2013). However, some of the bulkier single-strand lesions that distort the DNA helical 
structure, such as pyrimidine dimers caused by UV irradiation are processed by the 
NER pathway (Cleaver et al., 2009; Kamileri et al., 2012), which requires the excision 
repair cross-complementing protein 1 (ERCC1). DSBs are mainly restored either by HR, 
through the MRN complex and the proteins CtIP, replication protein A (RPA), BRCA1, 
BRCA2, RAD51 and PALB2 (Hartlerode & Scully, 2009; Moynahan & Jasin, 2010), or 
NHEJ processes. Factors involved in NHEJ include the Ku70 ⁄ Ku80 complex, DNA-PK 
catalytic subunit (DNA-PKcs), the Artemis nuclease, XLF, XRCC4, and DNA ligase IV 
(Lieber, 2010; Zimmermann & de Lange, 2014). Replication errors results in base 
mismatches, which are repaired through the so-called MMR pathway (Hsieh & Yamane, 
2008), essentially managed by proteins encoded by MSH2 and MLH1 genes. The 
ubiquitin-mediated activation of the FA pathway plays a key role in restoring the 
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intrastrand or interstrand crosslinks. Finally, translesion synthesis and template 
switching allow DNA to continue to replicate in the presence of DNA lesions that would 
otherwise halt the process. Therefore, both mechanisms are usually considered to be 
part of the DDR. The mechanisms that control the integrity of telomeric DNA in human 
chromosomes constitute a barrier against mutations and genome instability, although 
are not considered to belong to the DDR by some authors (Artandi & DePinho, 2010).  
 
Cell-cycle-checkpoint and chromosome-segregation machineries interact with 
core components of the DDR, thus facilitating the DNA repair to occur before mitosis 
and ensuring the correct genetic material segregation to daughter cells (Hanahan & 
Weinberg, 2011) (Figure 1). 
 
Figure 1. Overview of the diverse spectrum of DNA damage and the DNA damage 
response. The major repair pathways and key proteins used to process each type of damage are 
shown. BER: base excision repair; NER: nucleotide excision repair; HR: homologous repair; 
NHEJ: non-homologous end-joining (Adapted from Lord et al, Nature, 2012).  
 
 
DSBs are among the most deleterious DNA lesions, which if unrepaired or 
repaired incorrectly can cause cell death or genome instability that may lead to cancer. 
Within the homologous recombination response, the MRE11–RAD50–NBS1 (MRN) 
complex is recruited to the damaged DNA sites, and phosphorylates a variant H2A 
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histone (H2AX) (Fernandez-Capetillo et al., 2004), thus intensifying the signal and 
recruiting new molecules to the DSB lesion, where lastly the ATM (ataxia-telangiectasia 
mutated) kinase is activated. MRN complex itself is also capable of phosphorylating 
ATM (Bakkenist & Kastan, 2003; Falck et al., 2005; Lee & Paull, 2005). Once activated, 
ATM orchestrates a large number of downstream effectors (Matsuoka et al., 2007). 
Phosphorylation of CHK2 (checkpoint kinase 2) on Thr68 inactivates members of the 
CDC25 family of dual-specificity phosphatases, responsible for ruling cell cycle 
divisions (Donzelli & Draetta, 2003), and consequently leads to cell cycle arrest. ATM-
dependent phosphorylation of the tumor-suppressor BRCA1, as well as its inhibitor 
CtIP, leads to DSB repair and cell cycle arrest in the S phase (Cortez et al., 1999) 
(Gatei et al., 2001). In this regard, CHK2, previously activated by ATM, likewise 
phosphorylates and activates BRCA1. ATM also phosphorylates and activates p53 
(Ser15), what triggers cell cycle arrest in the G1 phase or cell death.  
 
As a final result, p53 Ser46 phosphorylation mediated apoptosis will be 
achieved by a number of kinases such as ATM, DNA-PK, PKCδ, DYRK2 and HIPK2 
(D'Orazi et al., 2002; Komiyama et al., 2004; Saito et al., 2002; Taira et al., 2007; 
Yoshida et al., 2006). DYRK2 (dual-specificity tyrosine-(Y)-phosphorylation regulated 
kinase 2) is regulated by Mdm2 under normal conditions (Taira et al., 2010). Upon 
genotoxic stress, both proteins dissociate due to a direct phosphorylation on DYRK2 
(Thr33 and Ser369) by ATM. Once this occurs, DYRK2 phosphorylates p53 on serine 
46 and the apoptotic response finally takes place (Figure 2).  
 
3.1.2. Aberrations in DNA Damage Responses and Human Disease 
 
DNA damage response in human physiology plays a central role as can be 
proved from the broad spectrum of defects displayed by individuals carrying mutations 
in DDR genes. DDR genetic syndromes primarily produce neurological defects, 
infertility, immunological defects, premature aging, stem cell exhaustion and cancer 
development (Ciccia & Elledge, 2010). 
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Figure 2. DNA damage response (DDR) pathway in response to DNA double-strand breaks 
(DSBs), trough MRN complex sensor (Adapted from Stolz et al, Clin Cancer Res, 2011 and 
Sulli et al, Nat Rev Cancer, 2012). 
 
 
Maintenance of genomic integrity by the DDR is critical to prevent 
tumorigenesis, as indicated by the cancer-prone phenotype of several DDR syndromes, 
such as XP syndrome or Bloom syndrome (BS), where DDR alterations increase the 
risk of skin cancer and melanoma or lymphomas, leukemias and carcinomas, 
respectively (Ciccia & Elledge, 2010; Negrini et al., 2010).	
 
Dysfunctionality of the DDR is noticeable at an early stage in the development 
of neoplasia. Markers of DSBs, such as nuclear γH2AX foci (a histone phosphorylation 
event that occurs on chromatin surrounding a DSB), are markedly elevated in some 
precancerous lesions (Bartkova et al., 2006; Halazonetis et al., 2008). For 
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precancerous lesions to progress to mature tumors, it is thought that critical DSB and 
cell-cycle checkpoint proteins, such as ATM, ATR (ataxia telangiectasia and Rad3-
related protein), and the master ‘gatekeeper’ protein p53 become inactivated, due to 
mutations, deletion or loss of heterozygosity of the genes (Brosh & Rotter, 2009; 
Hosoya & Miyagawa, 2014). This leads to an ineffective DNA damage repair before 
mitosis and cells proceed through the cell cycle with DNA lesions intact, increasing the 
chance of mutagenesis (Lord & Ashworth, 2012). 
 
Nevertheless, controversy exists regarding the expression of DDR proteins in 
tumors, as both activation and inactivation are observed in a large spectrum of sporadic 
cancers. DDR proteins activation may serve as a barrier to the malignant progression 
and metastasis. For instance, augmented autophosphorylation of ATM and ATM-
dependent phosphorylation of CHK2 are reported in early-stage tumors (Bartkova et al., 
2005; Gorgoulis et al., 2005), and hyper activation of ATM has been observed in late-
stage breast tumor tissues (Sun et al., 2012). Increased expression of a large list of 
other DDR proteins (NBS1, RAD50/51, CHK1/2, CDC25s, DNA-PK, BRCA1, ERCC1, 
APE1, and PARP1) has been also reported in various cancers, being in some cases 
associated with resistance to chemotherapy! (Abbotts & Madhusudan, 2010; Hannay et 
al., 2007; Mego et al., 2013; Olaussen et al., 2006; Takenaka et al., 2007; Taron et al., 
2004). On the contrary, inactivation of some of the previous proteins (ATM, MRN 
complex, CHK2, RAD51, BRCA1/2, and ERCC1) is also frequently observed in other 
cohort of tumors. These data indicate the common aberration of the DDR is evident in 
sporadic cancers, presenting an important role in the development of the disease!
(Hosoya & Miyagawa, 2014). 
 
3.1.3.  Targeting DNA Damage Response Pathways for Cancer Therapy 
 
DDR defects have already been exploited in cancer treatment, being the targets 
of drugs commonly used in chemotherapy and radiotherapy. One example is the use of 
platinum salts (carboplatin, cisplatin, oxaliplatin), that induce covalent crosslinks 
between DNA bases. An alternative approach to chemotherapy is the design of drugs 
that target specific DDR components, such as agents that cause SSB or DSB by 
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trapping topoisomerase I or II enzymes on DNA (camptothecin or irinotecan and 
etoposide, respectively) (Ciccia & Elledge, 2010). These topoisomerase inhibitors could 
be regarded as the first generation of DDR ‘targeted’ agents (Pommier et al., 2010). 
Within the next generation of DDR inhibitors, PARP1 inhibitors as targeted therapy are 
included. They have been successfully used to treat tumors that carry mutations in HR 
genes, such as BRCA1 and BRCA2 (Jackson & Bartek, 2009). 
 
Furthermore, given the elevated levels of DNA damage in cancer cells 
compared to healthy ones, one approximation as selective anticancer therapy is further 
increase the amount of DNA damage (by inhibition of DDR components) in combination 
with other chemotherapeutic drugs, thus augmenting cancer cell death. For instance, it 
would be interesting, in order to kill the malignant cells and not the normal ones, to 
block the alternative repair pathway that is activated in cancer cells to partially 
compensate their already disrupted DNA repair pathway. This is the principle of action 
of PARP inhibitors commented before, which if in addition are combined with 
radiotherapy, effectively prohibit tumor malignant transformation through the synergistic 
effect. In order to further disrupt the DNA repair pathway responsible for the tumor 
survival and drug resistance, one potential treatment considered is to target the cell 
cycle checkpoint by inhibiting ATM (the predominant kinase involved in the activation of 
the response to DSB) or CHK1 and CHK2.  Indeed, it has been proved the preferential 
toxicity of ATM, DNA-PK and CHK1 inhibitors towards cancer cells after treatment with 
genotoxic agents (Bolderson et al., 2009). Interestingly, ATM and DNA-PK depletion 
have been shown to sensitize TP53 and ATM mutant tumor cells to genotoxic agents, 
respectively (Jiang et al., 2009). Emerging evidence suggests that CHK1 and CHK2 
inhibitors may have high antitumor properties due to their key roles in the specific 
regulation of checkpoint control of the cells. This suggest a further advantage of 
inhibiting the checkpoint kinases over their upstream activators ATM and ATR involved 
additionally in the activation of DNA repair (Tse et al., 2007; Welch et al., 2007). 
AZD7762, XL844 and PF-47736 combined with other DNA damaging agent exert 
enhanced cytotoxicity toward malignant tumor cells (Janetka et al., 2007). Regarding 
p53, the blockade of its function (that leads to G2 checkpoint abrogation) can sensitize 
 Introduction !
!18 
cancer cells to cytotoxic agents as it has been demonstrated in squamous cell 
carcinoma of the head and neck in response to radiotherapy (Tian et al., 2015). 
 
 
3.2. CHK2  
 
3.2.1. CHK2 family context 
 
As mentioned above, the serine threonine kinase CHK2 is a highly conserved 
protein critical in the DDR signaling pathway, which is activated to protect the cells 
against nuclear DNA alterations (Stracker et al., 2009; Zannini et al., 2014). CHK2 is a 
CAMK protein kinase of the Rad53 family, whose structure is similar in all eukaryotes. 
Human, mouse, rat, zebra fish and C. elegans homologues of the protein kinase are 
called CHK2, whereas the homologues in other species present alternative names: 
Xcds1 (X. laevis), cds1 (S. pombe), Rad53 (S. cerevisiae) and Dmnk (D. 
melanogaster). Rad53 was the founding member of the “CHK2 family” of check-point 
kinases and was first identified in 1994 (Bartek et al., 2001). 
 
3.2.2. Structure and function of CHK2 
 
Human CHK2 protein, encoded by Chk2 gene located on chromosome 
22q12.1, presents 543 residues and contains three different functional domains: an N-
terminal region rich in serine-glutamine and threonine-glutamine pairs, called SQ/TQ 
cluster domain (SCD, residues19–69), which satisfy the primary substrate motif for 
ATM/ATR kinases, especially residues 67–70; a forkhead-associated domain (FHA, 
residues 113–175) responsible for interactions with other proteins in trans and for 
affecting functional domains within the protein itself in cis; and a canonical kinase 
domain (residues 220–486) that occupies almost the entire C-terminal half of CHK2, 
containing Asp as a catalytic residue at the active site and an activation loop within its 
key functional elements (Ahn et al., 2004; Buscemi et al., 2004; Li et al., 2002a; 
Matsuoka et al., 2007) (Figure 3). 
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Upon activation, CHK2 phosphorylates and regulates several proteins involved 
in different steps of the DDR, such as DNA repair, cell cycle regulation, apoptosis and 
p53 signaling (Antoni et al., 2007). To date, 24 substrate proteins of this kinase have 
been described in human cells, amongst which BRCA1, CDC25A and CDC25C, HDMX, 
PML (Promyelocytic Leukemia) and E2F1 are included (Chaturvedi et al., 1999; Pereg 
et al., 2006; Stevens et al., 2003; Yang et al., 2002; Zannini et al., 2014; Zhang et al., 
2004). Interestingly, both BRCA1 and PML substrates interacts with CHK2 in the 
absence of DNA damage but, following gamma irradiation, BRCA1 is phosphorylated at 
Ser988 and PML at Ser117 in a CHK2-dependent manner, resulting in subsequent 
inhibition of binding with CHK2 and leading to the induction of DNA repair (Ahn et al., 
2004; Zhang et al., 2004). Regarding cell cycle regulation, CHK2 phosphorylates 
CDC25A (Ser123) and CDC25C (Ser216) phosphatases after DNA damage, thus 
mediating CDC25A SCFβTCRP-dependent turnover and persistent cytoplasmic CDC25C 
localization that prevents the G2/M transition. Accordingly, CHK2 phosphorylation of 
these phosphatases induces cell cycle arrest in response to DNA damage (Ahn et al., 
2004; Takai et al., 2002). CHK2 phosphorylates E2F-1 at Ser364 in response to the 
DNA-damaging agent etoposide (ETP), regulating its stabilization and transcriptional 
activity, what represents a potentially relevant pathway through which CHK2 regulates 
DNA damage-induced apoptosis (Stevens et al., 2003). Importantly, CHK2 presents the 
ability to regulate p53 activity, either directly through Ser20 phosphorylation (Chehab et 
al., 2000), or indirectly phosphorylating other proteins, such as Che-1, STRAP, HDMX 
(Choi et al., 2013; Zhang et al., 2004). Ser20 phosphorylation by CHK2 stabilizes p53 
protein, enhancing its potential to positively regulate the expression of factors that are 
involved in DNA repair, cell death and cell-cycle control. Likewise, p53 phosphorylation 
by CHK2 at residues Ser366 and Thr387 has been described, being involved in cell 
cycle arrest at G1/S and G2/M and in p53 acetylation regulation, respectively (Bruno et 
al., 2006). Several substrates of CHK2 (p53, PML, E2F1, BRCA1, and CHK2 itself) are 
also proteins phosphorylated by ATM, reflecting the possible redundant role of both 
proteins and suggesting that CHK2 can act as a relay for ATM and/or as a salvage 
pathway when ATM is inactivated (Matsuoka et al., 2007; Wang et al., 2004; White et 
al., 2006). 
 
 Introduction 	
	20 
3.2.3. Localization and expression of CHK2 
 
CHK2 is predominantly -if not exclusively- located in the nucleus of mammalian 
cells, what was expected for a protein involved in the regulation of the DNA-damage 
checkpoint. CHK2 often localizes distinct subnuclear bodies or ‘foci’, and, indeed, 
ionizing radiation triggers its accumulation at sites of DNA strand breaks (upon DNA 
damage, activated Thr68-CHK2 colocalizes with 53BP1, H2AX, and NBS1 in nuclear 
foci). However there is an intriguing localization of CHK2 in human neuronal cells, 
where it has a predominantly cytoplasmic localization, in contrast to other cell and 
tissue types. ATM–CHK2 pathway in neurons might have a specialized cytoplasmic role 
possibly related to protection from against oxidative stress. In fact, patients with ataxia-
telangiectasia, who lack functional ATM, suffer from severe neurodegeneration, which 
probably reflects the elevated oxidative stress and progressive neuronal cell death. 
Although CHK2 is mainly nuclear in somatic cells, several reports document the 
presence of a subpopulation of CHK2 at centrosomes. Strikingly, in embryonic stem 
cells, CHK2 has been shown to localize exclusively at the centrosomes as well as 
in Drosophila melanogaster embryos (DmCHK2 homologue). On the other hand, 
Chouinard and colleagues demonstrated that CHK2 localizes exclusively in the nucleus 
of cells in interphase and that a small portion was localized to centrosomes in mitotic 
cells (for what PLK1 activity was required), from late prophase until cytokinesis 
supporting a role for CHK2 during mitosis (Chouinard et al., 2013).  
 
Studies of mammalian CHK2 messenger RNA expression indicated a broad but 
variable CHK2 distribution, with the highest levels in the testis, bone marrow and 
immune system and gastrointestinal tract. According to its function, CHK2 is generally 
expressed in cells of proliferating, as well as terminally differentiated, non-proliferating 
tissue compartments (Bartek et al., 2001). Regarding protein expression, the kinase is 
markedly present in almost all human tissues with the exception of adipose and soft 
tissue, and a low expression exists in brain or muscle tissues. Generally, tumor tissues 
show a higher expression of CHK2 compared with its respective non-tumor one. Most 
cancer tissues presents moderate to strong nuclear staining, but several cases of renal 
cancers are negative or weakly stained (Protein Atlas).  
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3.2.4. CHK2 regulation 
 
CHK2 exists as an inactive monomer in unperturbed cells. Following DNA 
damage, mainly DSB, CHK2 undergoes dimerization and consequently, becomes 
active. In order to achieve the kinase dimerization, several phosphorylation steps are 
needed. This first activating phosphorylation step of CHK2 is performed by ATM at 
Thr68, and depends on the integrity of its FHA domain, since one P-Thr68-CHK2 
molecule binds to the FHA domain of second molecule. Phosphorylation at Thr68 is the 
initiating event for dimerization and activation since its maintenance is not required for 
sustained kinase activity. The subsequent activation step is attributable to 
autophosphorylation of CHK2 on residues Thr383 and Thr387 within the auto-inhibitory 
loop, resulting in kinase activation. An extra autophosphorylation event at Ser516 (C-
terminal) is required for full kinase activation (Ahn et al., 2004; Bartek et al., 2001; Guo 
et al., 2010a; Lovly et al., 2008) (Figure 3). 
 
 
Figure 3. Scheme of CHK2 protein structure. SCD, FHA and Kinase domains are included. 
Phosphorylated threonine (T) and serine (S) residues needed for CHK2 activation are shown. 
 
 
Although CHK2 activation control mechanisms have been widely described, 
very little is known about its inactivation and degradation processes. Serine/threonine 
protein phosphatases 1 and 2A (PP1 and PP2A) and protein phosphatase 1D (WIP1) 
have been characterized as responsible to inactivate CHK2. Under normal conditions, 
B'α subunit of PP2A binds to the SQ/TQ repeat region of CHK2 and negatively 
regulates the kinase through its de-phosphorylation at multiple sites (Ser19, 33, and 35 
and Thr68); therefore modulating its kinase activity over substrates such as CDC25C. 
However, the interaction of both proteins is disrupted after DNA damage. PP1 
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phosphatase cooperates with PP2A to maintain CHK2-T68 unphosphorylated in 
undamaged cells (Carlessi et al., 2010; Freeman et al., 2010). On the other hand, WIP1 
association with CHK2 inhibits its Thr68 phosphorylation and consistent activation 
under DNA damage, resulting in the repression of CHK2 kinase activity toward 
CDC25C (Fujimoto et al., 2006). 
 
 Likewise, during the last decade several evidences have suggested that 
ubiquitination is an important control process in CHK2 turnover. The ubiquitin protease 
USP28 regulates the CHK2-p53-PUMA pathway; major regulator of DNA-damage-
induced apoptosis in response to DSB. USP28 is required to stabilize both CHK2 and 
53BP1 in response to DNA damage (Zhang et al., 2006). CHK2 has been reported as a 
new substrate of the E3 ubiquitin ligase RING finger protein 8 (RNF8) in humans, which 
ubiquitinates CHK2 diminishing this way its abundance and activation in response to 
ionizing radiation (Feng & Chen, 2012). Finally, it has been demonstrated that p53-
induced RING-H2 protein (PIRH2) is the E3 ubiquitin ligase of CHK2 in mice. PIRH2 
interacts with CHK2 and mediates its polyubiquitylation and proteasomal degradation, 
thus regulating its turnover and its function. Interestingly, USP28 forms a complex with 
PIRH2 and CHK2 and antagonizes PIRH2-mediated polyubiquitylation and proteasomal 
degradation of CHK2 (Bohgaki et al., 2013).  
 
Even though the recent identification of these enzymes as regulators of CHK2 
through ubiquitination in response to DNA damage, the mechanisms required to 
maintaining the steady-levels of such a relevant protein remain poorly understood. 
 
3.2.5. SIAH2 
 
The E3 ubiquitin ligase SIAH2 (seven in absentia homolog 2) belongs to the 
RING finger E3 ubiquitin ligases (Hu et al., 1997; Schnell & Hicke, 2003). In humans, 
two subunits (SIAH1 and SIAH2) have been described, which are codified by different 
genes and present similar and redundant functions (Della et al., 1993; Holloway et al., 
1997). Human SIAH2 is a 324 amino acid dimeric protein that mediates ubiquitination 
and subsequent proteasomal degradation of target proteins. It presents a RING (Real 
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Interesting New Gen) catalytic domain in its N-terminal that recruits E2 ubiquitin 
conjugating enzymes, two zinc-finger motifs and a substrate-binding domain (SBD) in 
its C-terminal (House et al., 2009; Polekhina et al., 2002) (Figure 4A).  
 
 
Figure 4. SIAH2 protein structure and function. A. SIAH2 full sequence showing the three 
basic domains: RING, Zinc Fingers and SBD. B. Schematic overview of SIAH2 function trough 
some substrates.  
 
SIAH2 is responsible for ubiquitination and proteasomal degradation of specific 
substrates, either through direct interaction or through binding to adapter proteins 
(Calzado et al., 2009; Li et al., 2002b; Matsuzawa & Reed, 2001; Sarkar et al., 2012). 
SIAH2 controls the expression of substrates involved in crucial processes such as 
apoptosis, tumor suppression, cell cycle, transcription and cell signaling. Within the 
most relevant SIAH2 substrates described to date PML, N-CoR, HDAC3, TRAF2, β-
catenin, HIPK2 and DYRK2 are included. SIAH2 binds and targets for proteasome-
mediated degradation the putative tumor suppressor PML (Promyelocytic leukemia 
protein), leading to the loss of its transcriptional co-activating properties and a reduction 
Figure 4
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in the number of endogenous PML nuclear bodies (Fanelli et al., 2004). SIAH2 also 
interacts with N-CoR, TRAF2, β-catenin and HDAC3, mediating their proteasomal 
degradation (Habelhah et al., 2002; Topol et al., 2003; Zhang et al., 1998; Zhao et al., 
2010). Two members of the dual-specificity tyrosine-regulated kinase (DYRK) family of 
kinases, HIPK2 and DYRK2 have been previously described by our group as SIAH2 
substrates, existing in both cases a mutual regulation between the ligase and the 
kinase, wherein the kinases also phosphorylate SIAH2 regulating its function (Calzado 
et al., 2009; Perez et al., 2012). However the key role of SIAH2 on the regulation of 
hypoxia response stands out, mainly due to its ability to alter the expression of hypoxia-
inducible transcription factor 1 alpha (HIF-1α), which occurs through the degradation of 
the Hypoxia-inducible factor prolyl hydroxylases (PHDs), (Appelhoff et al., 2004; Le 
Moan et al., 2011; Nakayama et al., 2004) (Figure 4B). 
 
SIAH2 expression can be controlled at a transcriptional level by estrogens, 
different transcription factors (WNT5a and E2F1) and small noncoding microRNA (MiR-
146b) (Frasor et al., 2005; Knauer et al., 2015; Liao et al., 2013; Topol et al., 2003; Xie 
et al., 2009). Different post-translational modifications able to modify SIAH2 activity 
have been described, such as their ability to autoubiquitinate and the phosphorylation 
mediated by upstream kinases (Hu & Fearon, 1999). To date, only 3 kinases able to 
phosphorylate SIAH2, modifying its activity, have been described: p38 MAPK, HIPK2 
and DYRK2. p38 MAPK phosphorylates murine SIAH2 in Thr24 and Ser29 increasing 
SIAH2-mediated degradation of PHD3 (Khurana et al., 2006). In this sense, phospho-
mutant SIAH2 shows weaker association with PHD3, while phospho-mimic SIAH2 
associates as the wild type does and is localized within the perinuclear region, 
suggesting that phosphorylation of SIAH2 affects its subcellular localization and, 
therefore, the degree of its association with its substrates. Likewise, the 
serine/threonine kinase HIPK2 is described to phosphorylate human SIAH2 in Thr26, 
Ser28 and Ser68 thus negatively affecting its stability and weaking its interaction with 
HIPK2 (Calzado et al., 2009). The highly related HIPK2 protein, DYRK2, has also been 
identified as SIAH2 interaction partner that phosphorylates it in a minimum of five 
residues (Ser16, Thr26, Ser28, Ser68, and Thr119), leading to an increase in the 
SIAH2 ability to trigger the HIF-1a-mediated transcriptional response and angiogenesis 
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(Perez et al., 2012). On the other hand, the deubiquitinating enzyme USP13 increases 
SIAH2 stability by attenuating its activity to degrade both itself and its substrates prolyl 
hydroxylase 3 and Spry2 (Sprouty2). It is worth noting that in melanoma cancer cells 
USP13 levels are decreased under hypoxia thereby relieving SIAH2 inhibition and 
increasing its activity (Scortegagna et al., 2011). 
 
 
3.3. DYRK2 
 
3.3.1. DYRK family 
 
The Dual-specificity tyrosine-regulated (DYRK) family of kinases belongs to the 
CMGC group, and is divided in turn into three subfamilies according to the homology 
within their kinase domain: DYRK kinases, homeodomain-interacting protein kinases 
(HIPKs), and pre-mRNA processing protein 4 kinases (PRP4s). DYRK subfamily 
members have been found in all eukaryotes and share common structural, biochemical, 
and functional properties with their ancestors in yeast (the founding member Yak1p was 
discovered in budding yeast more than 20 years ago). In mammals, DYRK subfamily 
comprises DYRK1A and DYRK1B (class I), DYRK2, DYRK3, and DYRK4 (class II). 
Homologues of DYRK1A and DYRK1B have been reported in Caenorhabditis elegans 
(MBK-1 and MBK-2), whereas homologues of class II DYRKs exist in Drosophila 
melanogaster (minibrain, dDyrk2, and dDyrk3). The five members of the subfamily 
share the kinase domain as well as a sequence just upstream of the kinase domain 
named the DYRK homology (DH)-box, what reflects the conservation among the 
different members at the protein level (Aranda et al., 2011). 
 
DYRK1A, founding member of the family, is the best well known among the rest 
isotypes and maps to the DSCR (Down Syndrome Critical Region) of chromosome 21 
(Guimera et al., 1996; Shindoh et al., 1996; Song et al., 1996). Besides being involved 
in neurological disorders such as Down syndrome, it is also implicated in calcium 
signaling by phosphorylating NFAT (Gwack et al., 2006) and cell polarity maintenance 
in Schizosaccharomyces pombe (Tatebe et al., 2005). Furthermore it is embroiled in 
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various biochemical pathways as it is able to phosphorylate many other substrates such 
as: STAT3 (Matsuo et al., 2001), eIF2B and Tau (Woods et al., 2001). DYRK1B 
mediates cell survival and differentiation and is highly expressed in muscle tissues (Lee 
et al., 2000; Mercer et al., 2005; Mercer & Friedman, 2006). It has been reported to 
phosphorylate among other substrates p21Cip1 (Zhou et al., 2001) and class II HDACs	
(Deng et al., 2005). DYRK3 is highly produced in hematopoietic cells and testis. It 
reduces apoptosis in response to cytokine starvation in hematopoietic cells (Geiger et 
al., 2001) and has been shown to phosphorylate SIRT1 (Guo et al., 2010b), myelin 
basic protein and histones H2b and H3 (Lord et al., 2000). DYRK4 is the least known 
isoform of all the DYRK family members. It is exclusively expressed in the testis and 
helps the process of spermiogenesis (Sacher et al., 2007). 
 
3.3.2. Structure and function of DYRK2 
 
Human DYRK2, encoded by Dyrk2 gene located on chromosome 12q15, is a 
528 amino acid (aa) protein that contains the following functional domains: first, as the 
rest of the members of its subfamily, a kinase domain (residues 149-462) and a DH box 
necessary for the formation of tertiary structure in the N-terminus; additionally, it 
presents two functional domains, the N-terminal autophosphorylation accessory regions 
1 and 2 (NAPA1 and NAPA2), shared by class II DYRK proteins, and a nuclear 
localization signal (NLS) (Becker et al., 1998; Soundararajan et al., 2013) (Figure 5A). 
Two isoforms of human DYRK2 resulting from 5’-UTR alternative splicing have been 
reported, which differ in their N-termini domain (short isoform: 528 aa, long isoform: 601 
aa). 
 
DYRKs are defined as dual-specificity protein kinase because they have 
tyrosine phosphorylation activity restricted to autophosphorylation so as to become 
active and serine/threonine phosphorylation activity on exogenous substrates. Indeed, 
no phosphorylated tyrosines have been found in any DYRKs substrate to date. DYRKs 
require phosphorylation of the activation loop (with a conserved YXY sequence; Y307-
T-Y309 in the case of DYRK2) to achieve full activity.  This autocatalytic process occurs 
during the translation of the protein, when a transient intermediate form, helped by the 
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NAPA domain that provides a chaperone-like function, is auto phosphorylated at the 
second tyrosine within the activation loop. The specificity of this intermediate for 
tyrosines is lost on completion of translation, and kinase activity becomes restricted to 
threonine and serine (Han et al., 2012; Kinstrie et al., 2010; Lochhead et al., 2005). 
 
 
Figure 5. DYRK2 protein structure and function. A. Representation of DYRK2 structure, 
showing the functional domains. B.  Schematic overview of DYRK2 function trough some 
substrates.  
 
DYRK2 is involved in regulating key developmental and cellular processes such 
as neurogenesis, cell proliferation, cytokinesis, and cellular differentiation. Substrates 
for DYRK2 by serine/threonine phosphorylation share consensus phosphorylation sites: 
R/Kxx(x)S/TP/V, wherein S or T is usually followed by a proline	 (Gwack et al., 2006; 
Maddika & Chen, 2009; Yoshida, 2008). Despite the crucial role of this kinase, 
especially in tumor development and progression, there are only 18 DYRK2 substrates 
described to date: Stat3 (Matsuo et al., 2001), eIF2Bε, Tau (Woods et al., 2001), 
Glycogen synthase (Skurat & Dietrich, 2004), NFAT (Gwack et al., 2006), SNR1 
(Kinstrie et al., 2006), p53 (Taira et al., 2007), Gli2 (Varjosalo et al., 2008), Katanin p60 
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(Maddika & Chen, 2009), c-Jun and c-Myc (Taira et al., 2012), SIAH2 (Perez et al., 
2012), Tert (Jung et al., 2013), hPXR (Ong et al., 2014), Snail (Yamaguchi et al., 2015), 
TBK1 (An et al., 2015), Rpt3 (Guo et al., 2016) and CP110 (Hossain et al., 2017) 
(Figure 5B). 
 
Several of the prior DYRK2 substrates are involved in cancer processes. Ten 
years ago, a finding of great importance described a major role of DYRK2 as concern 
the regulation of cell physiology upon DNA damage: DYRK2-dependent p53 
phosphorylation at Ser46, which leads to the induction of cellular apoptosis (Taira et al., 
2007). The important cell cycle regulators c-Jun and c-Myc are also phosphorylated by 
DYRK2, leading to is proteasomal degradation in the G1/S transition. Therefore, the 
maintenance of the steady-levels of these transcription factors by DYRK2 prevents an 
aberrant cell proliferation (Taira et al., 2012). Our group previously demonstrated that 
SIAH2 is a substrate for DYRK2 phosphorylation, taking place a mutual regulation 
between both enzymes under hypoxia and genotoxic stress (Perez et al., 2012). 
Moreover, it has been reported a relevant role for DYRK2 regarding proliferation and 
invasion of cancer cells, by the regulation of the Tert subunit of the Telomerase (Jung 
et al., 2013) and Snail	 (Mimoto et al., 2013; Yamaguchi et al., 2015), respectively. 
Recently, it has been described that the proteasome is dynamically phosphorylated 
during the cell cycle at Thr25 of the 19S subunit Rpt3 by DYRK2, leading to enhanced 
substrate translocation and degradation what finally results in  breast tumor formation in 
mice (Guo et al., 2016; Huibregtse & Matouschek, 2016). These findings demonstrate 
the biological significance of DYRK2 function in regulating cell proliferation and 
tumorigenesis (Figure 6). 
 
3.3.3. Localization and expression of DYRK2 
 
DYRK2 has a cytoplasmic subcellular localization under normal conditions 
(Becker et al., 1998; Leder et al., 1999), although it accumulates in the nucleus in 
response to genotoxic stress (Taira et al., 2007). This nuclear accumulation depends 
on the NLS domain of the kinase and on a release from Mdm2 degradation (Taira et al., 
2010). 
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Figure 6. DYRK2 role in cancer. Schematic overview of DYRK2 involvement in the different 
phases of the carcinogenic process. 
 
 
Studies of DYRK2 messenger RNA expression indicated a low expression in 
human tissues, with the exception of gastrointestinal tract and immune system. 
Concerning protein expression, the kinase is markedly present in almost all human 
tissues with the exception of adipose and soft tissue and the highest levels in Liver & 
gallbladder and Kidney & urinary bladder (Protein Atlas).  
 
While mutations of DYRK2 are not often found in cancer cells (the majority of 
them are missense mutations, with the exception of S471X, a nonsense mutation that 
lacks kinase activity! (Nihira & Yoshida, 2015), a deregulated expression was described 
by several groups. Further research to elucidate DYRK2 expression in human tumors is 
needed as different observations have been reported. It has been observed a high 
expression of DYRK2 in lymphatic system, in muscle-rich tissues, such as skeletal 
muscle and heart, and in neuroblastoma, esophagus and lung tumors (Miller et al., 
2003; Park et al., 2002; Varjosalo et al., 2008). On the other hand, it has been 
described a reduced or abolished DYRK2 expression in multiple human tumor tissues, 
which correlates with a shorter survival in the case of lung cancer (Yamashita et al., 
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2009) and invasiveness in the case of human breast cancer (Taira et al., 2012). 
Likewise, recent published data correlates low DYRK2 expression with breast cancer 
recurrence (Enomoto et al., 2014), as well as poor prognosis in colorectal cancer (Yan 
et al., 2016) and hepatocarcinoma (Zhang et al., 2016). Moreover, DYRK2 has been 
also proposed as a suppressor and potential prognostic marker for bladder cancer 
(Nomura et al., 2015) and liver metastasis of colorectal cancer (Ito et al., 2017) and as 
predictive marker for clinical responses to everolimus in hormone receptor-positive 
breast cancer (Mimoto et al., 2017).  
 
3.3.4. DYRK2 regulation 
	
DYRK2 is controlled under normal conditions by Mdm2, resulting in constitutive 
ubiquitination and proteasome degradation. Afterwards DNA damage, ATM 
phosphorylates DYRK2 on Thr33 and Ser369, which enable DYRK2 to escape from 
degradation by being dissociated from Mdm2 and to induce its kinase activity toward 
p53 at Ser46 in the nucleus. Thus, ATM augments nuclear stabilization of DYRK2 by 
inhibiting MDM2 in the apoptotic response to DNA damage (Taira et al., 2010). 
Furthermore, DYRK2 is controlled by MAP3K10 affecting its activity in the Hedgehog 
signaling pathway. MAP3K10 directly phosphorylates DYRK2 on Ser376 and Thr308. It 
is worth pointing out the closeness of the latter target residue to tyrosine 309, a critical 
activating autophosphorylation site found in all DYRK kinases (Varjosalo et al., 2008). 
Under hypoxic conditions, SIAH2 mediates DYRK2 polyubiquitination and subsequent 
proteasome degradation, which dampens the ability of DYRK2 to fuel the hypoxic 
response and alters the p53-dependent apoptosis in response to DNA damage (Perez 
et al., 2012). Moreover, the centrosomal protein Cep78 controls the scaffold function of 
DYRK2 due to its binding to the EDD-DYRK2-DDB1VprBP E3 ligase complex.  This 
interaction inhibits the complex activity, affecting centriole length and cilia assembly, 
and therefore, centrosome homeostasis (Hossain et al., 2017). Finally, it has been 
recently reported how miRNAs are also capable to regulate DYRK2 expression. DYRK2 
was negatively regulated by miR-622 via a specific targeted binding site within the 
3'UTR. Interestingly, decrease of miR-622 expression suppresses migration and 
invasion by targeting regulation of DYRK2 in colorectal cancer cells (Wang et al., 2017). 
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Besides the biochemical regulation of DYRK2, there exists two natural 
compound, harmine from Banisteriopsis caapi and leucettine from the marine sponge 
alkaloid leucettamine B, with the ability to inhibit DYRK kinase activity (Gockler et al., 
2009; Tahtouh et al., 2012). 
 
3.3.5. CDC25A 
 
Cell division cycle 25A (CDC25A) is a member of the CDC25 family of highly 
conserved dual-specificity phosphatases (dephosphorylates both tyrosine (Y) and 
threonine (T) residues). They are key regulators of normal cell division and mediators of 
the checkpoint response to DNA damage. During normal cell division they play a 
fundamental role in transitions between cell cycle phases, via dephosphorylation and 
consequent activation of Cyclin-dependent kinases (CDK) / Cyclin complexes. To date, 
CDK/Cyclin complexes are the only known substrates for CDC25 phosphatases 
(Boutros et al., 2007). The three isoforms of the family, CDC25A, CDC25B and 
CDC25C, are essential for the proper execution of the cell cycle, although it has been 
shown that CDC25A alone is sufficient for initiation of each step in the cell cycle 
(Ferguson et al., 2005).  
 
The human CDC25A protein, encoded by Cdc25A gene located on 
chromosome 3p21.31, has 524 amino acid residues, with two distinct regions: a C-
terminal catalytic domain and an N-terminal regulatory domain that contains 
phosphorylation sites involved in regulating protein stability and protein-protein 
interaction. Some of these sites constitute functional regulatory domains, such as DSG 
and KEN motifs. Besides, the regulatory domain also presents nuclear localization 
sequence (NLS) and nuclear exportation sequence (NES), which determine the 
subcellular location of CDC25A (Shen & Huang, 2012) (Figure 7A). Two isoforms of 
human CDC25A have been reported of which transcript variant 1 contains 121 
nucleotides more (from 793 to 914) than transcript variant 2. 
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Figure 7. Scheme of CDC25A structure and function. A. Scheme of CDC25A protein. 
Regulatory and catalytic domains are represented, including DSG and KEN regulatory motifs and 
phosphorylated residues involved in the regulation of the phosphatase. B. Role of CDC25A in cell 
cycle regulation, showing the feedback loops generated with CDK/Cyclin complexes.  
 
 
 In mammalian cells, CDK/Cyclin complexes are kept inactive by 
phosphorylation on specific residues. Activation of these complexes by 
dephosphorylation is needed to lead cells to go into cell cycle progression, task that is 
mediated by CDC25 phosphatases. While CDC25B and CDC25C promote G2/M 
progression by primarily dephosphorylating CDK1 at T14/Y15, CDC25A plays a more 
extensive role in assisting both G1/S and G2/M progression. CDC25A is an unstable 
protein whose cellular levels are regulated by periodic synthesis and by ubiquitin 
mediated proteolysis. In late G1 phase, CDC25A RNA and protein levels increase as 
cells are stimulated to enter the cycle from quiescence, as a result of E2F-1- and c-
Myc-mediated transcriptional activation (Galaktionov et al., 1996; Vigo et al., 1999). 
CDC25A mainly activates the CDK2/Cyclin E and CDK2/Cyclin A complexes during the 
G1–S transition, by removing CDK2 T14 and Y15 inhibitory phosphorylations. In turn, 
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CDK2 creates an auto-amplification loop further phosphorylating and activating 
CDC25A, what contributes to S phase progression by recruiting the essential replication 
factor CDC45 and DNA polymerase on replication origins. Moreover, during G1-S 
transition CDC25A plays another role through the activation of CyclinD-CDK4/6 
complexes, by removing CDK4 Y17 and CDK6 Y24 respectively (Iavarone & 
Massague, 1997; Terada et al., 1995). Likewise, CDK4/6-CyclinD complexes mediate 
the phosphorylation of CDC25A on S40 during G1, decreasing its stability in a ßTrCP-
dependent manner (Dozier et al., 2017). Furthermore, CDC25A also has a remarkable 
role in the G2/M transition, by activating CDK1/Cyclin B complexes through the 
revoking of its phosphate groups on T14 and Y15. Once active, CDK1/Cyclin B 
complexes contribute to initiate chromosome condensation, what lastly allow cells 
moving from interphase to mitosis. As it occurs with previous CDK/Cyclin complexes 
mentioned above, CDK1/Cyclin B generates a feedback loop (through CDC25A 
phosphorylation on S18 and 116) that stabilizes the phosphatase, allowing control of 
the G2-M transition (Boutros et al., 2007; Busino et al., 2004) (Figure 7B).    
 
   Due to its major function, CDC25A regulation results essential for the proper 
cell division. To ensure timely progression through the various phases of the cell cycle, 
the phosphatase expression and activity is tightly regulated by many mechanisms, 
including alternative exon splicing, phosphorylation–dephosphorylation cycles, 
interactions with partners such as 14-3-3 proteins, intracellular localization and cell-
cycle controlled degradation. CDC25A is constantly turned over in cycling cell. It first 
appears in late G1, and until mitosis, continuous de novo CDC25A synthesis is 
counterbalanced by its degradation through the!ubiquitin–proteasome pathway (Busino 
et al., 2004). Two ubiquitin ligase complexes have been described to mediate CDC25A 
ubiquitylation during cell cycle: APC/CCdh1 and SCFβTCRP. Each complex act at distinct 
stages of the cell cycle (at the end of mitosis and in S and G2 phases, respectively) and 
specific recognition motifs in CDC25A are required for the interaction. Specifically, 
SCFβTCRP binding is dependent of phosphorylation of serine residues before and/or 
within the DSG motif, while interaction with APC/CCdh1 is dependent upon a KEN motif 
without apparent requirement for post-translational modifications (Busino et al., 2003; 
Donzelli et al., 2002). The phosphorylation of the N-terminal regulatory domains is 
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performed by several kinases, including the CDK/Cyclin complexes themselves, CHK1, 
CHK2 and p38. CHK1 controls the proper timing of mitotic onset by phosphorylating 
CDC25A and thereby creating a 14-3-3 binding site to prevent its interaction with 
CDK1/Cyclin B. CDC25A is predominantly expressed in G1 and stabilized in mitosis 
through CDK1/CyclinB-mediated phosphorylation (Ser18 and 116). At the end of 
mitosis, CDC25A levels rapidly decrease owing to its degradation, mediated by 
APC/CCdh1-dependent ubiquitylation. In S and G2 phases, CDC25A is targeted for 
proteasome-mediated degradation by SCFβTCRP, requiring previous phosphorylation of 
serine clusters by CHK1 (Ser76, 124, 178, 279, 293), CHK2 (Ser124, 178, 279), p38 
(Ser76, 124), CK1A (Ser82), NEK11 (Ser82, 88) and another possible as yet unknown 
kinase (Boutros et al., 2007; Busino et al., 2004; Honaker & Piwnica-Worms, 2010; 
Melixetian et al., 2009). Moreover, a recent study identified Cul4B-DDB1DCAF8 as a new 
CDC25A E3 ligase, whose function is dependent of previous deacetylation at lysine 150 
by HDAC3 (Wu et al., 2016).  
 
As mentioned above, CDC25A is a key target of the checkpoint machinery 
activated in response to DNA damage. It is specifically and rapidly degraded by the 
proteasome via phosphorylation of kinases of the activated ATM/ATR–CHK1/2 
pathway, in order to stop cell cycle progression meanwhile DNA damaged is repaired, 
preventing cells with chromosomal abnormalities from progressing through cell division 
(Reinhardt & Yaffe, 2009). The basal turnover of CDC25A controlled by CHK1 
phosphorylation (residues Ser124, 178, 279, 293) is accelerated in response to UV light 
or IR treatment, when an increase in phosphorylation at Ser124 is detected. This leads 
to its ubiquitin-mediated destruction or loss of phosphatase activity and induces a G2 
arrest. IR-induced activation of CHK2 cooperates with CHK1 in phosphorylating 
CDC25A on serine 124, 178 and 293. It has also been demonstrated that CHK1 and 
p38 dependent Ser76 phosphorylation of CDC25A mediates its stabilization in response 
to UV-induced DNA damage (Boutros et al., 2006; Busino et al., 2004). 
 
 CDC25A overexpression, which can be caused by stabilization of the protein, 
accelerates the G1/S and G2/M transitions, leading to genomic instability and promoting 
tumorigenesis. This deregulated expression may be due to anomalous E2F1/c-Myc 
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E2F1/c-Myc transcriptional activity or alternatively to deregulations at different levels of 
the degradation pathway of CDC25A (disrupted CHK1/CHK2 activities, mutations in the 
ubiquitin ligases that mediate the degradation or even mutations in specific consensus 
sites (e.g. DSG motif) of the phosphatase itself) (Busino et al., 2004). CDC25A has 
been reported to be overexpressed (both at the mRNA and protein levels) in primary 
tissue samples from various human cancers, including breast, colorectal, lung 
pancreas, hepatocellular, thyroid and non-Hodgkin lymphoma among others, being 
highly associated with the malignancy and poor prognosis in cancer patients. For 
instance, CDC25A overexpression has been associated with shorter disease-free 
survival in breast, esophageal and hepatocellular carcinomas (Boutros et al., 2007; 
Kristjansdottir & Rudolph, 2004). Therefore, CDC25A inhibition is considered as a 
potential therapeutic target against cancer. However, most of the inhibitors described to 
date show cross-reaction with the three CDC25 isoforms, lacking specificity over 
CDC25A (Brenner et al., 2014). 
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Cancer is an evolutionary disease fueled by genomic instability due to 
alterations of DNA Damage Response pathway, among others. Although there is a 
great knowledge of the signaling networks that comprise this complex pathway, further 
research is needed to elucidate new molecular mechanisms whereby DNA-damage 
cells tip the balance to apoptosis or tumorigenesis. In this sense, it is relevant to study 
how kinases involved in the DDR pathway, such as CHK2 and DYRK2, exerts its 
function during tumour development and progression, through the identification of new 
substrates that take an active part in these processes. Thereby, our understanding of 
the tumorigenic process will be improved, opening a road to the development of new 
therapeutic strategies against cancer. 
 
 
The aims of this search project have been the following: 
 
1. Identify and analyse new kinases (CHK2 and DYRK2) substrates involved in 
the DNA Damage Response pathway. 
 
2. Study the biochemical consequences of CHK2 and DYRK2 regulation over 
their identified substrates, with a special focus under genotoxic stress 
conditions.  
 
3. Investigate the functional implications of CHK2 and DYRK2 regulation over 
their identified substrates in carcinogenesis, through analyses in cancer cells 
and tissues.  
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5.1. Cell culture and hypoxia 
  
 HEK-293T (Human embryonic kidney cells), HeLa (human cervical cancer 
cells), U2OS (human osteosarcoma cell line), A549 (human lung cancer cells) wild type 
(wt)/cisplatin resistant (CPR), control MEFs (mouse embryonic fibroblasts) and 
Siah1a−/− /Siah2−/− MEF cells were maintained in DMEM. H727 (human lung cancer 
cells) and MOR (human lung cancer cells) wt/CPR cells were maintained in RPMI. Both 
DMEM and RPMI were supplemented with 10% FCS, 2 mM L-glutamine and 1% (v/v) 
penicillin/streptomycin at 37 ºC in a humidified atmosphere containing 5% CO2. Cell 
lines are routinely tested to be free of mycoplasma and cross contamination. Cell lines 
validation was performed by a multiplex PCR with Geneprint10 System (Promega, 
Madison, WI, U.S.A.). HEK-293T, HeLa, U2OS, control MEFs and H727 cells were 
obtained from ATCC. A549 wt/CPR cells and Epo-Luc plasmid were a gift from Dr. M. L. 
Schmitz (University of Giessen, Germany). MOR wt/CPR cells were from Sigma-Aldrich 
(St. Louis, MO, U.S.A.).  Siah1a−/− /Siah2−/− MEF cells were obtained from Dr. David 
Bowtell and Dr. Andreas Möller. HIPK2−/− HEK-293T cells were kindly provided by Dr. 
Laureano de la Vega (University of Dundee, Scotland, UK). Hypoxia was induced by 
cultivation of cells in a New Brunswick Galaxy 48 R incubator (Eppendorf, Hamburg, 
Germany) at defined O2 concentrations.  
 
5.2. Reagents 
 
MG-132 was purchased from Enzo Life Science (Lausen, Switzerland), 
Caffeine (84677) was from Fluka (Bucharest, Romania), Calyculin A (sc-24000) from 
Santa Cruz (Santa Cruz, CA, U.S.A.) and the rest of the reagents were from Sigma-
Aldrich: Etoposide (E1383), Cisplatin (P4394), 5-Fluorouracil (5-FU) (F6627), 
Cicloheximide (C7698), Thymidine (T9250) and Adriamycin/Doxorubicin hydrochloride 
(44583). Scramble control oligonucleotide siRNA non-targeting pool (D-001810-10-20) 
and the siGENOME SMARTpool against SIAH2 (M-006561-02), ON-TARGET plus 
SMARTpool against CHK2 (L-003256-00) and ON-TARGET plus SMARTpool against 
DYRK2 (L-004730-00-0010) were purchased from Dharmacon (Waltham, MA, U.S.A.). 
The effect of siRNA on protein expression was assessed after 48 h of transfection for 
CHK2 and SIAH2 and after 72 h for DYRK2. E1, E2-UbcH5c, Ubiquitin and CDC25A 
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(ab90763) human recombinant proteins were purchased from Abcam (Cambrigde, UK). 
DYRK2 (14-669) recombinant protein was from Merck (Massachusetts, U.S.A.). 
 
5.3. Transfection and plasmids  
 
Transient transfections were performed with Rotifect (CarlRoth, Karlsruhe, 
Germany) according to manufacturer instructions and harvested 48 h after transfection. 
DNA amounts in each transfection were kept constant upon addition of empty 
expression vector.  
Flag-CHK2, KD (Kinase Dead) and T68A, Myc-CHK2, KD were a gift from Dr. 
H. Piwnica-Worms (Washington University School of Medicine, U.S.A.). GST-CHK2 
plasmid was a gift from Dr. Stephen J. Elledge (Harvard Medical School, U.S.A.). HA-
CHK2, KD, GST-CHK2-ΔSCD and ΔFHA plasmids were kindly provided by Dr. David F. 
Stern (Yale University School of Medicine). HA-CHK2 S456A was provided by Dr. Carol 
Prives (Department of Biological Sciences, Columbia University, New York). CHK2-GFP 
was provided by Dr. L. Zannini (Istituto Nazionale dei Tumori, Milan, Italy). Myc-CHK2 
ΔSCD and ΔFHA were kindly provided by Dr. S-Y Shieh (Institute of Biomedical 
Science, Taiwan). Flag-CHK2 S19A was a gift from Dr. Domenico Delia (Istituto 
Nazionale dei Tumori, Milan, Italy). Flag-PHD3 was a gift from Dr. Frank S. Lee 
(Pennsylvania School of Medicine). Flag-SIAH2 and RM (Ring Mutant, H98A/C101A), 
Flag-SIAH2-3A (triple mutant) and Flag-SIAH2-3D (phosphomimic), HA-SIAH2 and RM, 
His-Ubiquitin and Flag-HIPK2 and KD were described previously (Calzado et al, 2009). 
Flag-DYRK2 and KD (kinase dead, K251R), GFP-DYRK2 and KD and HA-
DYRK1A/DYRK3/DYRK4 were gifts from Dr. Susana de la Luna (Centre for genomic 
regulation, Barcelona, Spain). Myc-DYRK2 and KD were cloned by PCR (from Flag-
DYRK2 and KD) to pCMV-Tag3B vectors. GFP-DYRK1B was kindly provided by Dr. 
Walter Becker (Rwth Aachen University, Germany). Flag-CDC25A was kindly provided 
by Dr. Peter Stambrook (University of Cincinnati, Ohio, U.S.A.). Flag-CDC25A-S88A, 
Flag-CDC25A-ΔKEN and Flag-CDC25A-DM were obtained by performing directed 
mutagenesis from Flag-CDC25A plasmid using the QuikChange II Site-Directed 
Mutagenesis Kit (Agilent Technologies, California, U.S.A.) according to manufacturer 
instructions. All the constructs generated were confirmed by DNA sequencing. 
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5.4. BEAS-2B squamous-cell differentiation model 
 
BEAS-2B cells were purchased from SIGMA (SIGMA; European Collection of 
Cell Cultures, Salisbury, UK. 95102433) and maintained in serum free LHC-9 medium 
(Life Technologies, Carlsbad, CA, U.S.A.) at 37 °C in a humidified atmosphere 
containing 5% CO2. Squamous differentiation was acquired after culturing in LHC-9 
medium enriched with 10% FBS during 7 days. 
 
5.5. Cell synchronization  
 
HeLa cells were synchronized in G1 phase of the cell cycle by Double 
Thymidine Block. For first blockade 2 mM thymidine was added to the cells during 18 h. 
Then cells were washed with 1X PBS and incubated with fresh media for 9 h. Next, 2 
mM thymidine was added again for second blockade during 15 h. Finally, cells were 
released by washing with 1X PBS and adding fresh DMEM and harvested after 0 h (G1 
fraction), 3.5 h (S fraction), 6 h (G2 fraction) and 10 h (M fraction). Checking of the 
cellular fractions was performed by flow cytometry (FACS analyses).  
 
5.6. FACS analyses  
 
For cell cycle analysis, cells were fixed in 70% cold ethanol at -20 ºC overnight. 
After that cells were washed with PBS once and then stained with 1 mg/mL propidium 
iodide (PI) and treated with RNase A (50 U/mL) for 2 h at 37 ºC in darkness. For 
apoptosis studies, cells were harvested and washed in cold PBS and then resuspended 
in binding buffer consisting of 10 mM Hepes, 140 mM NaCl and 2.5 mM CaCl2 pH 7.4. 
Cells were stained with Annexin V, Alexa Fluor 488 conjugate (Molecular Probes by 
Life Technologies, Carlsbad, CA, U.S.A.) and propidium iodide. Cell cycle distribution 
and apoptosis were determined by BD FACSCanto™ flow cytometer (BD Biosciences, 
San Jose, CA, U.S.A.) using BD FACSDiva™ software. 
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5.7. Cell lysis and Western Blotting 
 
Soluble fractions were obtained after lysis of cells in NP-40 buffer [50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1% (v/v) NP-40, 10% (v/v) glycerol, 10 mM NaF, 1 mM 
Na3VO4, aprotinin (10 μg/ml), leupeptine (10 μg/ml), pepstatin (1 μg/ml) and 1 mM 
PMSF saturated]. After centrifugation the supernatants were mixed with SDS sample 
buffer (50mM Tris-HCl pH6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 
10% glycerol) and boiled at 95 °C. Proteins were resolved on SDS-PAGE gels and 
blotted to polyvinylidene difluoride (PVDF) membranes using a semi-dry transfer. After 
blocking with non fat milk or BSA in TBST buffer, primary antibodies were added. 
Appropriate secondary antibodies coupled to horseradish peroxidase were detected by 
an enhanced chemiluminescence system (USB). 
 
5.8. Antibodies 
 
Mouse monoclonal antibodies against Flag (M2) and anti-β-actin (AC-74) were 
purchased from Sigma-Aldrich, anti-HA epitope (3F10), anti-GFP (11814460001) and 
anti-myc (9E10) from Roche Molecular Biochemicals (Mannheim, Germany), anti-p53 
phospho Ser46 (2521), anti-ubiquitin (P4D1), anti-CHK2 Thr68 [(C13C1)-2197], anti-
CDC25C Ser216 (9528), anti-CHK2 Ser516 (2669) and  anti-p53 Ser20 (9287) from 
Cell Signaling Technology (Danvers, MA, U.S.A.), anti-DYRK2 (sc-66867), anti-SIAH2 
(sc-5507) and anti-p53 (sc-126) from Santa Cruz, anti-CDC25A (MA5-13794) from  
Thermo Fisher Scientific (Waltham, MA U.S.A.), anti-phospho-S/T-Pro (05-368) from 
Merck (Massachusetts, U.S.A.). Rabbit polyclonal antibodies recognizing 
phosphorylated threonine 26 and serines 28 and 68 of SIAH2 were raised by NeoMPS 
(San Diego, California, U.S.A.). Rabbit polyclonal antibodies recognizing 
phosphorylated threonine 119 of SIAH2 were raised by Abyntek (Vizcaya, Spain). Alexa 
Fluor 647 goat anti-mouse IgG1 (A21235) antibody was from Life technologies 
(Carlsbad, CA, U.S.A.). Secondary HRP-coupled antibodies were obtained from 
Jackson ImmunoResearch Laboratories (Baltimore, U.S.A.).  
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5.9. Immunoprecipitation  
 
Cells were first washed in PBS and collected by centrifugation. The cell pellet 
was lysed in IP buffer [(50 mM Hepes pH 7.5, 50 mM NaCl and 1% Triton X-100) 
supplemented with 5 mM EGTA, 20 mM Na4P2O7, 50 mM NaF, 1 mM Na3VO4, 2 mM 
PMSF and 10 μg/ml of leupeptine, aprotinin and pepstatin]. Cell lysates were incubated 
with 1 μg of the indicated antibodies for 6 h at 4 ºC. Antibodies were then isolated with 
25 μl of protein A/G Sepharose (Santa Cruz). Imnunoprecipitated proteins were then 
washed five times in IP buffer and eluted in 1.5X SDS sample buffer. Samples were 
immunoblotted as described before. 
 
5.10. Immunofluorescence 
 
Cells were grown on coverslips and 48 h after transfection fixed with 3.7% of 
pre-warmed paraphormaldehyde/PBS for 10 minutes. Cells were then permeabilized 
with 0.1% Triton X-100/PBS for 15 minutes blocked with 3% BSA/PBS and incubated 
overnight with primary antibodies. After being washed with PBS and incubated for 45 
min with the secondary antibody they were mounted on glass slides with mounting 
medium with DAPI (Vectashield). Fluorescence images were captured using confocal 
laser scanning microscope LSM 5 EXCITER (Carl Zeiss MicroImaging GmbH) using a 
40X/1.30 oil objective (EC Plan-Neofluar) and ZEN 2008 software (Carl Zeiss 
MicroImaging GmbH). Images were analysed using the ImageJ v 1.45 software 
(http://rsbweb.nih.gov/ij/). The Costes’ approach was employed for co-localization 
analysis between green (Alexa 488) and red (Alexa 647) images to determinate the 
Pearson’s correlation coefficient (R). SIAH2 wild type and phospho mutant versions 
were visualized on a BD Pathway 855 Bioimager in a non-confocal mode. 
 
5.11. Immunohistochemical analysis  
 
Immunohistochemical staining was performed on formalin-fixed, paraffin-
embedded human lung tumors. Staining of cancer cells was scored and compared to 
peripheral normal lung tissue. Five-micrometer sections from tumor samples were 
prepared for tissue slides. Sections were deparaffinised in xylene, and rehydrated in a 
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graded ethanol series and distilled water. Staining with hematoxylin–eosin (H & E) and 
the rabbit polyclonal anti-DYRK2 antibody (AP7534a; Abgent, San Diego, California, 
U.S.A.) at 1:50 dilution was performed overnight at 4 °C. Antigen retrieval for sections 
to be stained with the polyclonal anti-DYRK2 antibody was performed by incubating the 
slides in 1 mM EDTA pH 8.0 in a 98 °C–100 °C steamer for 30 minutes. DYRK2 IHC 
staining was evaluated as follows: 0, no staining or faint cytoplasmic staining in less 
than 10% of tumor cells; 1+, faint cytoplasmic staining inmore tan 10% of tumor cells; 
2+, weak or moderate cytoplasmic staining inmore than 10% of tumor cells; 3+, more 
than 10% of strong cytoplasmic staining. 0 or 1+ staining intensity was considered as 
DYRK2 negative, whereas 2+ or 3+ was considered as DYRK2 positive. 
 
5.12. Enrichment of His-Tagged Proteins 
 
Cells were collected in PBS and pellets were dissolved in lysis buffer [50 mM 
Tris-HCl buffer pH 8.0 containing 8M urea, 50 mM Na2HPO4, 300 mM NaCl, 0.5% (v/v) 
NP-40, 10 mM imidazole and 1 mM β-mercaptoethanol]. Samples were sonified and 
cell debris was removed by centrifugation. His-ubiquitin tagged proteins were isolated 
with 40 μl of equilibrated Ni-NTA resin (Qiagen) for 4 h at room temperature. After 
centrifugation precipitates were washed once with lysis buffer, once with wash buffer 1 
(10 mM Tris HCl, pH 8.0 containing 8M Urea, 100 mM Na2HPO4, 10 mM imidazole and 
1 mM β-Mercaptoethanol) and twice with Wash buffer 2 (the same composition of wash 
buffer 1 but at pH 6.3). Proteins were eluted in SDS sample buffer containing 200 mM 
imidazole and analyzed by immunoblotting. 
 
5.13. GST pull-down assay 
 
Recombinant GST-SIAH2 proteins (wt, ΔC and ΔN) and GST-CHK2 (wt, ΔSCD 
and ΔFHA) were produced in Escherichia coli BL21 cells and purified with Glutathione-
Sepharose 4B (GE Healthcare) according to standard protocols. Soluble fusion proteins 
(10 μg) were incubated at 4 ºC overnight with 30 μl of glutathione-sepharose beads. 
Sepharose beads were then washed with IP buffer and resuspended in SDS sample 
buffer for further inmunoblot analysis. 
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5.14. In vitro ubiquitination analysis 
 
Recombinant GST-CHK2 was incubated or not with different combinations of 
E1, E2-UbcH5c, E3 (GST-SIAH2) and ubiquitin human recombinant proteins in 
ubiquitylation buffer (50 mM Tris, 5 mM MgCl2, 0.1% Tween-20, 1 mM DTT) and ATP 
2mM. After 60 min of incubation at 37 ºC reactions were stopped adding SDS sample 
buffer and samples were subjected to Western Blot analyses.  
 
5.15. In vitro phosphorylation analysis  
 
GST-SIAH2 fusion protein was incubated with GST-CHK2 protein in kinase 
buffer (20 mM Hepes pH 7.5, 10 mM MgCl2, 1 mM DTT and 0.1 mM ATP). After 60 min 
of incubation at 30 ºC reactions were stopped adding SDS sample buffer. Samples 
were then immunoblotted with anti-PhosphoSer28-SIAH2 and anti-CHK2 antibodies. 
Similarly, commercial CDC25A recombinant protein was incubated with DYRK2 
recombinant protein in kinase buffer and proceeded as mentioned before. Samples 
were immunoblotted with anti-Phospho-S/T-Pro, anti-CDC25A and anti-DYRK2 
antibodies.  
 
5.16. γ-phosphatase assay 
 
Cells were lysed in NP-40 buffer without phosphatase inhibitors. Then samples 
were treated with γ-phosphatase following manufacturer’s instructions (New England 
Biolabs). Reactions were stopped with SDS buffer and samples inmunoblottted. 
 
5.17. Peptide array-binding assay  
 
Overlapping dodecapeptides of SIAH2 protein were automated spotted on 
cellulose membranes by using Fmoc-protection chemistry. Membrane was blocked 
overnight in non fat milk in TBS buffer and incubated during 6 hours with 60 nmol of 
recombinant GST-CHK2 protein or GST protein for control. Then primary anti-CHK2 
antibody was added and mouse secondary antibodies coupled to horseradish 
peroxidase were revealed by enhanced chemiluminescence system (USB) on 
autoradiographic films.  
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5.18. mRNA extraction and qPCR  
 
Cells were harvested and washed twice with PBS. The cell pellet was lysed and 
total RNA was extracted using the High Pure RNA Isolation Kit (Roche Molecular 
Biochemicals, Mannheim, Germany). RNA integrity was checked on an agarose gel 
(Bio-Rad Universal Hood II). mRNA retrotranscription was performed with the iScript 
cDNA Synthesis kit (Bio-Rad, Madrid, Spain). Real-time PCR was employed with iQ™ 
SYBR® Green Supermix (Bio-Rad) in an iCYCLER detection system (Bio-Rad). 
Amplification efficiencies were validated and normalized against β-actin, and fold 
change in gene expression was calculated using the 2−ΔΔCt method. The following 
primers were used:  
CHK2-F: 5’-CGGATGTTGAGGCTCAGCA-3’ 
CHK2-R: 5’-TATGCCCTGGGACTGTGAGG-3’ 
CDC25A-F: 5'-GCACTCGGTCAGTGTTGAAG-3' 
CDC25A-R: 5'-CATGGGCCTTCTCTGGATTA-3' 
HPRT-F: 5’-AATTATGGACAGGACTGAACGTCTTGCT-3’ 
HPRT-R: 5’-TCCAGCAGGTCAGCAAAGAATTTATAGC-3’ 
 
5.19. Luciferase reporter assays 
 
Cells were collected in PBS and lysed in luciferase buffer (25 mM Tris–phosphate 
pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol). Luciferase assay 
was performed using Luciferase Assay Reagent (Promega, Madison, WI, U.S.A.) 
according to the manufacturer’s instructions and  luciferase activity was measured in a 
luminometer Autolumat LB9510 (EG&G Berthold, U.S.A.). Luciferase activity in different 
samples was normalized with protein concentration. 
 
5.20. Cell viability assays 
 
Cell viability was measured by MTT assay. MTT reagent (5 mg/ml, Sigma-
Aldrich) was added to cells and incubated for 3 h at 37 °C in darkness. The formazan 
crystals were solubilized by the addition of 100 μL DMSO and the absorbance at 550 
nm was measured using a Multifunction Microplate Reader (TECAN GENios Pro, 
Switzerland). All determinations were carried out in triplicate. 
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5.21. Statistical analysis 
 
 Data are expressed as mean ± SD. Differences were analyzed by Student's t 
test. Statistical analyses were performed using GraphPad Prism version 6.00 
(GraphPad, San Diego, CA, U.S.A.). P0.05 was considered significant. Images were 
analyzed and quantified using the ImageJ v1.45 software.  
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6.1. CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2 
 
6.1.1. SIAH2 interacts and colocalizes with CHK2 
 
 In order to investigate the mechanisms responsible for maintaining the steady-
levels of CHK2, we tested a set of different E3 ligases for their ability to interact with 
CHK2 (data not shown). As SIAH2 showed positive results in our screening, we 
decided to focus on this protein in detail. We first co-expressed Flag-CHK2 alone or in 
the presence of hemagglutinin epitope (HA)-tagged SIAH2 in HEK-293T cells, and 
performed coimmunoprecipitation assays. Flag-CHK2 coimmunoprecipitated efficiently 
with HA-SIAH2 (Figure 8A). Similar results were obtained the other way round (Figure 
8B). Similarly, immunoprecipitation of endogenous CHK2 pulled down SIAH2 (Figure 
8C). 
 
Figure 8. CHK2 interacts with SIAH2. (A) HEK-293T cells were transfected with expression 
plasmids encoding HA-SIAH2 and Flag-CHK2 as indicated, and after 36 h the proteasome 
inhibitor MG-132 (10 µM) was added for another 12 h to avoid SIAH2 autodegradation. Cells 
were lysed and subjected to immunoprecipitation (IP) using anti-HA antibody. After elution, Flag-
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CHK2 protein was detected by western blotting (WB). A small fraction (5%) of the lysate was 
tested for the occurrence of the indicated proteins by immunoblot (INPUT). The positions and 
molecular weights (in kDa) are indicated. We show a representative blot of three independent 
experiments. (B) The experimental settings were similar to (A) with the exception that the 
inmunoprecipitation was performed using anti-Flag antibody for CHK2. We show a representative 
blot of three independent experiments. (C) HeLa cells were lysed and a fraction subjected to IP 
with anti-SIAH2 antibody or Ig control. The precipitates were subjected to WB analysis with anti-
CHK2 or anti-SIAH2 antibodies. We show a representative blot of three independent 
experiments.  
 
 
 Then, we analyzed the subcellular localization of both proteins and the effect of 
DNA damage by ETP treatment. CHK2 and SIAH2 proteins mainly colocalize in the 
nucleus and no changes were observed in the cells stimulated with ETP (Figure 9).  
 
Figure 9. CHK2 colocalizes with SIAH2. U2OS cells were transfected with Flag-SIAH2 RM 
(RING Mutant) and CHK2-GFP and analyzed for the localization of both proteins by 
immunofluorescence. Nuclear DNA was stained with DAPI. Overlapping localization in merged 
pictures is shown in yellow. We show a representative picture. Correlation analysis revealed a 
high degree of colocalization with a value of 0.59 ± 0.06 for Pearson’s coefficient. No significant 
changes were observed in the cells stimulated with ETP (0.61 ± 0.07).  
 
Next, we wanted to study the effect of DNA damage on CHK2-SIAH2 
interaction. Coimmunoprecipitation experiments showed that the interaction between 
these two proteins was markedly reduced under ETP (Figure 10A and 10B), cisplatin or 
5-fluorouracil (5-FU) stimulation (Figure 10B). All these data support the existence of a 
CHK2-SIAH2 complex, which can be partially disrupted in response to DNA damage 
without impairing its subcellular colocalization.   
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Figure 10. DNA damage effect on CHK2-SIAH2 interaction. (A) HEK-293T cells were 
transfected with the indicated plasmids, and after 36h stimulated with ETP (10 µM) and MG-132 
for another 12 h. Cells were lysed, subjected to immunoprecipitation (IP) using anti-HA antibody, 
and the different proteins detected by WB. A small fraction (5%) of the lysate was tested by 
immunoblot for the occurrence of the indicated proteins (INPUT). We show a representative blot 
of four independent experiments. (B) HEK-293T cells were transfected with the indicated 
plasmids, and after 36 h stimulated with ETP (10 µM), cisplatin (5 µM) or 5-FU (0.5 µg/ml) as 
indicated, and MG-132 for another 12 h to avoid SIAH2 autodegradation. Cells were lysed, 
subjected to IP using anti-Flag antibody, and, after elution, detected by WB. A small fraction (5%) 
of the lysate was tested for the occurrence of the indicated proteins by immunoblot (INPUT). 
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6.1.2.  CHK2 shows a direct interaction with SIAH2 
 
 To study whether CHK2 and SIAH2 directly interact and to characterize the 
responsible domains of this interaction, we performed GST-pulldown assays. Flag-
CHK2 was brought down by full-length SIAH2 and also by two deletion mutants (N- and 
C-terminus) (Figure 11A). Similarly, Flag-SIAH2 was captured by full-length CHK2 and, 
to a lesser extent, by FHA or SCD domain-deleted mutants (Figure 11B).  
 
 
 
Figure 11. CHK2 shows direct interaction with SIAH2 by GST pull down assays. (A) HEK-
293T cells were transfected to express Flag-CHK2, lysed and incubated with GST-SIAH2 or 
deleted versions. After immunoprecipitation, CHK2 protein was detected by WB with anti-Flag 
antibody. The lower part shows the Coomassie-stained input material and a schematic 
representation of SIAH2-WT and its mutants. We show a representative blot of three independent 
experiments. (B) The experimental settings were similar to (A) with the exception that HEK-293T 
cells were transfected to express Flag-SIAH2, lysed and incubated with GST-CHK2 or deleted 
versions. We show a representative blot of three independent experiments. 
 
To identify the sites of direct interaction, we performed a peptide array 
experiment (Figure 12A). Detection of the bound material by antibodies showed that 
CHK2 binds four distinct domains of SIAH2. Likewise, SIAH2 showed interactions with 
two distinct sites of CHK2 (Figure 12B). Then, we compared the interaction between 
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SIAH2 and full-length CHK2 with FHA or SCD domain-deleted mutants by 
coimmunoprecipitation assay. As shown in Figure 13A, and in agreement with the 
results obtained in the GST pull-down assays, FHA or SCD domain-deleted mutants 
were captured to a lesser degree than full-length CHK2 by Flag-SIAH2. Lastly, we 
decided to compare the interaction between SIAH2 and CHK2 wild-type (wt) or CHK2 
kinase dead (KD) mutant by coimmunoprecipitation assays. These experiments 
revealed that the loss of CHK2 kinase activity does not affect the ability to interact with 
SIAH2 (Figure 13B). All these results clearly show a direct physical interaction of CHK2 
and SIAH2, suggesting the existence of more than one domain responsible for binding 
in both proteins. Similarly, these data indicate that SIAH2 interacts with CHK2 
monomeric and dimeric forms.  
 
 
 
 
 
Figure 12. Identification of direct interaction sites in CHK2-SIAH2 complex. (A) Schematic 
representations of SIAH2 and CHK2 with the regions responsible for interaction. Recombinant 
GST-CHK2 or GST-SIAH2 proteins (or GST control protein) were incubated with a peptide array 
library covering the complete sequence of SIAH2 or CHK2 respectively, and bound proteins were 
revealed by immunoblot. CHK2 binds to four distinct domains of SIAH2, while SIAH2 interacts 
with two domains in the lower part of CHK2. 
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Figure 13. Comparation of the interaction of SIAH2 with different CHK2 forms. (A) HEK-
293T cells were transfected with expression plasmids encoding Flag-tagged SIAH2, Myc-CHK2 
and FHA or SCD domain-deleted mutants as indicated, and after 36 h the proteasome inhibitor 
MG-132 (10 µM) was added for another 12 h to avoid SIAH2 autodegradation. Cells were lysed, 
subjected to immunoprecipitation (IP), and after elution detected by WB. A small fraction (5%) of 
the lysate was tested for the occurrence of the indicated proteins by immunoblot (INPUT). (B) 
HEK-293T cells were transfected with expression plasmids indicated, stimulated with MG-132 
during 12 h, lysed and subjected to IP using anti-Flag antibody. Protein expression was detected 
by western blotting with the indicated antibodies. A fraction of the lysate was used to test the 
expression of the indicated proteins (INPUT). We show a representative blot of three independent 
experiments.  
 
6.1.3.  SIAH2 mediates CHK2 ubiquitination and proteosomal degradation 
 
 Based on the ability of SIAH2 to lead the ubiquitination and proteosomal 
degradation of many of its interaction partners, we analyzed whether SIAH2 can 
degrade CHK2 through an ubiquitin/proteasome-dependent process. We coexpressed 
CHK2 with increasing amounts of SIAH2 or the ligase-deficient SIAH2 point mutant 
(SIAH2 RM). Expression of SIAH2 resulted in a dose-dependent decrease in CHK2 
protein levels in HEK-293T cells (Figure 14A). Similar results were obtained in MOR 
and A549 cells (Figure 14B). By contrast, CHK2 levels were not altered in the presence 
of the SIAH2 RM. A comparative assay with SIAH1 showed that SIAH2 is the only 
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member of the human family able to induce CHK2 degradation (Figure 14C). Then, we 
examined this effect in the presence or absence of the proteasome inhibitor MG-132. 
The addition of this inhibitor stabilized SIAH2 and significantly prevented CHK2 
degradation (Figure 14D). 
 
 
Figure 14. SIAH2 mediates proteasomal degradation of CHK2. (A) HEK-293T cells were 
transfected to express CHK2 and the levels were evaluated in response to increasing 
concentrations of SIAH2 wild type or SIAH2 RING mutant by WB. We show a representative blot 
of three independent experiments. (B) MOR and A549 cells were transfected to express CHK2 
and its levels were evaluated in response to increasing concentrations of SIAH2 wild type by WB. 
(C) HEK-293T cells were transfected to express CHK2 in the presence of SIAH1 or SIAH2. After 
36 h cells were lysed and protein expression analyzed by immunoblot. (D) Cells were transfected 
with the indicated plasmids to express CHK2 and increasing concentrations of SIAH2 in the 
presence or absence of MG-132. Cells were lysed and protein expression analyzed by WB. We 
show a representative blot of three independent experiments.  
 
Next, we decided to analyze the impact of SIAH2 expression at different levels 
on the endogenous CHK2. Increasing amounts of SIAH2 revealed a dose-dependent 
decrease in CHK2 protein levels without affect mRNA expression (Figure 15A). Then 
we analyzed the effect of SIAH2 inhibition by specific siRNA together with the effect of 
ETP stimulation, based on previous results by which DNA damage partially disrupted 
SIAH2-CHK2 interaction. SIAH2 depletion increases CHK2 levels (Figure 15B) as well 
as its half-life (Figure 15C), indicating that CHK2 basal levels can be regulated by this 
E3 ligase. In addition, ETP stimulation increased CHK2 stability as well as its half-life 
Figure 14
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(Figure 15C), which were not affected by SIAH2 inhibition. These changes were 
accompanied by an increase in CDC25C-Ser216 phosphorylation. Taken together, 
these results suggest that SIAH2 regulates CHK2 turnover through a mechanism 
occurring at the protein level, affecting its stability and activity. 
 
 We next examined the effect of SIAH2 on CHK2 ubiquitination in vivo and in 
vitro. We coexpressed His-Ubiquitin and HA-CHK2 with or without different 
concentrations of SIAH2 in the presence of MG-132, and analyzed the ubiquitination 
status of CHK2. As shown in Figure 16A, CHK2 polyubiquitination became more 
evident in the presence of increasing concentrations of SIAH2. By contrast, CHK2 
polyubiquitination was inhibited in the presence of the SIAH2 RM (Figure 16B). Then, 
we examined the effect of SIAH2 deficiency on the basal level of CHK2 
polyubiquitination, comparing control MEFs to Siah1a−/−/Siah2−/− MEF cells. 
Ubiquitination levels of CHK2 were significantly lower in the knockout MEFs lacking 
Siah1a and Siah2 (Figure 16C). Finally, we analyzed SIAH2 ability to directly 
ubiquitylate CHK2 through an in vitro ubiquitination assay. Polyubiquitination of CHK2 
was observed only in the presence of SIAH2 (Figure 16D).  
 
CHK2 phosphorylation is a relevant mechanism for the control of its activity and 
stability. After DNA damage, T68 phosphorylation leads to conformational changes that 
induce dimerization and full activation (Ahn et al., 2002; Xu et al., 2002). Similarly, S456 
phosphorylation is critical for the stability control by ubiquitination (Bohgaki et al., 2013; 
Kass et al., 2007; Kass et al., 2009). We decided to evaluate the effect of SIAH2 on 
CHK2 wt compared to CHK2 S456A and T68A mutants. As shown in Figures 17A and 
17B, both mutants were degraded in a similar way to CHK2 wt, indicating that the 
phosphorylation status of these residues is not relevant for the degradation mediated by 
SIAH2. Moreover, we compared the interaction between SIAH2 and CHK2 wt in the 
presence or absence of ATM-ATR inhibitor caffeine, or CHK2 S19A and T68A mutants 
by coimmunoprecipitation assays. These experiments revealed that CHK2 
phosphorylation status, at least in these important residues, is not relevant for the 
association with SIAH2 (Figure 17C). In the same sense, we evaluated the capacity of 
SIAH2 to degrade FHA or SCD domain-deleted mutants (Figure 17D). Although FHA 
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domain-deleted mutant was partially degraded, the expression of the SCD domain-
deleted mutant was not affected by SIAH2. 
 
Figure 15. SIAH2 degrades CHK2 at endogenous levels. (A) HEK-293T cells were transfected 
to express increasing amounts of SIAH2, harvested and lysed. One fraction was used to analyze 
endogenous CHK2 protein levels while another aliquot was used to analyze CHK2 mRNA levels 
by qPCR. Data are mean ± SD of n = 3. We show a representative blot of three independent 
experiments. Primer sequences are available upon request. (B) HEK-293T cells were transfected 
with SIAH2 or scrambled (control) siRNAs, after 4 days stimulated with etoposide (10 μM) during 
24 h as indicated, lysed and protein expression analyzed by immunoblot. We show a 
representative blot of three independent experiments. (C) HEK-293T cells were transfected with 
SIAH2 or scrambled (control) siRNAs and, after 4 days of culture, treated with the protein 
synthesis inhibitor cycloheximide (CHX) (40 μg/ml) for 4.5 and 9 h in the presence or absence of 
ETP (10 μM). Cell lysates were analyzed by immunoblot using actin expression as the loading 
control. The graph represents the mean ± SD of band density from 3 different experiments. 
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Figure 16. CHK2 ubiquitination in vivo and in vitro by SIAH2. (A) HEK-293T cells were 
transfected with expression plasmids encoding HA-CHK2, Flag-SIAH2 and His-Ubiquitin. After 36 
h cells were incubated in the presence of MG-132 (10 µM) during 12 h and lysed under 
denaturing conditions. His-tagged ubiquitin was purified with Ni-NTA agarose columns and 
ubiquitinated CHK2 was analyzed by WB. A fraction was tested for the occurrence of the 
indicated proteins (INPUT). We show a representative blot of three independent experiments.  
(B) The experimental settings were similar to (A) with the exception that Flag-SIAH2 RING 
mutant was transfected instead of the wild type form of the ligase. (C) Wild type and 
Siah1a−/−/Siah2−/− MEF cells were stimulated or not with MG-132 during 12h, lysed and subjected 
to immunoprecipitation using anti-CHK2 antibody. The precipitates were subjected to WB 
analysis with anti-CHK2 or anti-Ub antibodies. A small fraction of the lysate was tested for the 
occurrence of CHK2 (INPUT). We show a representative blot of three independent experiments. 
(D) In vitro ubiquitination of CHK2 with E1, E2 (UbcH5c), Ubiquitin and SIAH2 recombinant 
human proteins. Upon activation with ATP, the samples were incubated for 2 h at 30 ºC, and the 
reaction stopped by the addition of SDS-loading buffer. Ubiquitinated CHK2 proteins were 
visualized by WB using anti-CHK2 antibody. 
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Finally, we decided to study the effect of DNA damage on CHK2 degradation by 
SIAH2. ETP stimulation prevented CHK2 polyubiquitination (Figure 18A) and 
degradation by SIAH2 (Figure 18B), as well as increased its half-life (Figure 15C). 
Similar results were obtained after stimulation with cisplatin and 5-FU (Figure 18C). 
Collectively, these data show that SIAH2 stimulates basal CHK2 polyubiquitination, 
thereby identifying CHK2 as a substrate for SIAH2-mediated ubiquitination and 
proteasomal degradation. 
 
 
Figure 17. Effect of SIAH2 on CHK2 under its activation and stabilization. HEK-293T cells 
were transfected to express CHK2 wild type and the S456A (A) or the T68A mutant (B) in the 
presence or absence of SIAH2. After 36 h cells were lysed and protein expression analyzed by 
immunoblot with the indicated antibodies. (C) HEK-293T cells were transfected with the indicated 
plasmids, after 36 h stimulated with MG-132 for another 12 h and caffeine (3 mM) for another 2 h 
as indicated. Cells were lysed, subjected to immunoprecipitation (IP) and, after elution, protein 
expression was analyzed by immunoblot. A small fraction (5%) of the lysate was tested for the 
occurrence of the indicated proteins (INPUT). (D) HEK-293T cells were transfected with 
expression plasmids encoding HA-SIAH2, Myc-CHK2 and FHA or SCD domain-deleted mutants 
as indicated, after 36h cells were lysed and subjected to WB with the indicated antibodies. 
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Figure 18. Effect of DNA damage on CHK2 degradation by SIAH2. (A) HEK-293T cells were 
transfected with the indicated plasmids and, 24 h post-transfection, stimulated with ETP (10 μM) 
during 24 h and with MG-132 10 µM during 12 h. Cells were lysed under denaturing conditions, 
His-tagged ubiquitin was purified with Ni-NTA agarose columns and ubiquitinated CHK2 was 
analyzed by WB. An aliquot of the input material was also tested for correct protein expression 
(INPUT). (B) HEK-293T cells were transfected or not to express SIAH2, and 24 h post-
transfection stimulated with ETP (10 µM) during 24 h as indicated. Cells were lysed and protein 
expression was analyzed by immunoblot with the indicated antibodies. We show a representative 
blot of three independent experiments (C) The experimental settings were similar to (B) with the 
exception that cells were stimulated with cisplatin (5 µM) or (5-FU, 0.5 µg/ml) as indicated. 
 
 
6.1.4. CHK2 phosphorylates SIAH2 in at least three residues in vivo and 
in vitro 
 
 As we showed in previous works (Calzado et al., 2009; Perez et al., 2012), 
some kinase substrates of SIAH2 have the ability to phosphorylate this E3 ligase. 
Therefore, we tested the capacity of CHK2 to phosphorylate SIAH2. CHK2 
overexpression resulted in the presence of slower migrating SIAH2 bands, an effect not 
observed with CHK2 kinase dead mutant (KD) (Figure 19A). SIAH2 phosphorylation 
was analyzed with a specific phospho-SIAH2 antibody for Ser28 (Calzado et al., 2009). 
To confirm that the upshifted SIAH2 bands were phosphorylated forms, we incubated 
cell extracts with λ phosphatase. Treatment transformed the slower electrophoretic 
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mobility of SIAH2 bands into the faster migrating bands, and SIAH2 phosphorylation 
disappeared (Figure 19B). These results indicate that the upshifted SIAH2 bands 
observed after CHK2 wild-type overexpression represent hyperphosphorylated forms. 
 
 To examine the capacity of CHK2 to directly phosphorylate SIAH2, we 
performed an in vitro kinase assay. The presence of GST-CHK2 showed the 
occurrence of an upper band of GST-SIAH2 detected with a specific phospho-SIAH2 
antibody (Figure 19C), which disappeared after λ phosphatase treatment (Figure 19D). 
Next, we evaluated the CHK2 ability to phosphorylate endogenous SIAH2 by comparing 
phospho-SIAH2 endogenous levels of control cells to the cells where endogenous 
CHK2 was knocked down by siRNA treatment (Figure 20A). CHK2 inhibition caused a 
significant reduction of endogenous SIAH2 Ser28 phosphorylation. Taken together, 
these results clearly indicate that CHK2 can directly phosphorylate SIAH2. Once again, 
we examined the effect of ETP stimulation on SIAH2 phosphorylation by CHK2. As 
shown in Figure 20B and coherent with the previous results, stimulation with ETP 
decreased substantially SIAH2 phosphorylation levels mediated by CHK2. 
 
To identify the SIAH2 sites phosphorylated by CHK2, we used four different 
phospho-specific antibodies (Thr26, Ser28, Ser68 and Thr119) previously described 
(Perez et al., 2012). SIAH2 or point mutants of the phosphorylated amino acids to 
alanine were expressed either alone or together with CHK2, followed by detection of 
single-site phosphorylation (Figure 20C). CHK2 expression caused phosphorylation in 3 
different sites (Thr26, Ser28 and Ser68), but we did not observe any significant 
changes in Thr119. Ser28 mutation precluded phosphorylation at Thr26, probably due 
to the fact that these sites are very close and in the same epitope. Overall, these results 
clearly indicate that CHK2 directly phosphorylates SIAH2 at a minimum of three 
residues. 
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Figure 19. CHK2 phosphorylates SIAH2 in vivo and in vitro. (A) HEK-293T cells were 
transfected to express Flag-SIAH2 and increasing amounts of Flag-CHK2 wild type or Flag-CHK2 
kinase dead mutant (KD), and after 36 h, they were treated for 12 h  with the proteasome inhibitor 
MG-132 (10 µM).	 Cell lysates were analyzed by immunoblotting with the indicated antibodies. 
SIAH2 phosphorylation was seen by the upshifted band and also by the use of a specific antibody 
recognizing phosphorylated Ser28 of SIAH2. We show a representative blot of three independent 
experiments. (B) HEK-293T cells were transfected with the indicated plasmids and treated with 
MG-132 for 12 h. Cells were lysed in phosphatase inhibitor-free buffer in the absence or 
presence of l-phosphatase. Electrophoretic mobility was determined by immunoblotting and in 
parallel SIAH2 phosphorylation was analyzed with phospho-specific antibody for Ser28 of SIAH2. 
We show a representative blot of three independent experiments. (C) In vitro kinase assay was 
performed with active CHK2 recombinant protein and purified GST-SIAH2. Phosphorylation was 
determined with phospho-specific antibody for Ser28 of SIAH2, while protein levels were 
visualized by Coomassie staining (lower). (D) In vitro kinase assay was performed with active 
CHK2 recombinant protein and purified GST-SIAH2. The products of the reaction were treated or 
not with l-phosphatase, and phosphorylation was determined with a phospho-specific antibody 
for Ser28 of SIAH2. Coomassie staining of the GST proteins is shown in lower panel.  
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Figure 20. CHK2 phosphorylates SIAH2 in at least three residues. (A) HEK-293T cells were 
transfected with CHK2 or scrambled (control) siRNAs, lysed after 4 days of culture and CHK2 
and SIAH2 phosphorylation analyzed by WB. We show a representative blot of three independent 
experiments. (B) Cells were transfected to express HA-SIAH2 in the presence or absence of 
Flag-CHK2. 24h post-transfection cells were stimulated with ETP (6 µM) during 24 h, lysed and 
protein expression was analyzed by immunoblot with the indicated antibodies. SIAH2 
phosphorylation was analyzed with phospho-specific antibody for Ser28. We show a 
representative blot of three independent experiments. (C) HEK-293T cells were cotransfected 
with Flag-SIAH2 or the indicated SIAH2 point mutants either alone or along with CHK2 and 
treated with MG-132 for 12 h. Electrophoretic mobility was determined by WB and in parallel 
SIAH2 phosphorylation was analyzed with phospho-specific antibodies for the residues indicated. 
We show a representative blot of three independent experiments.  
 
6.1.5. Effect of SIAH2 phosphorylation on CHK2 turnover via 
ubiquitination and proteosomal degradation 
 
 Does SIAH2 phosphorylation by CHK2 control the degradation of this kinase 
through the ubiquitin/proteasome system? To address this issue, we transfected HEK-
293T cells with Flag-CHK2 or Flag-CHK2 KD with increasing amounts of Flag-SIAH2. 
CHK2 degradation by SIAH2 was independent of the presence of its kinase activity 
(Figure 21A). Next, we compared the capacity of the phosphorylation (SIAH2-3A) and 
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the phosphomimic (SIAH2-3D) mutants in the residues phosphorylated by CHK2 to 
degrade this kinase. Cells were transfected with Flag-CHK2 together with Flag-SIAH2-
WT, Flag-SIAH2-3A or Flag-SIAH2-3D, using Flag-SIAH2 RM as a negative control. As 
shown in Figure 21B, CHK2 was degraded to a similar way in the three cases. These 
results support the hypothesis that the phosphorylation state of SIAH2 does not alter its 
capacity to degrade CHK2. 
 
 Others and we have revealed how SIAH2 phosphorylation affects its activity on 
certain substrates. Although the former results indicated that this is not the case for 
CHK2, we decided to analyze the effect on other substrates as prolyl hydroxylase 3 
(PHD3). SIAH2 regulates Hypoxia-inducible factor 1-alpha (HIF-1α) expression mostly 
via PHD3 inhibition (Nakayama et al., 2004).! Cells were transfected with Flag-PHD3, 
together with different SIAH2 variants in the presence or absence of Flag-CHK2, and a 
luciferase construct controlled by the HIF-1-dependent erythropoietin promoter (Epo-
Luc). SIAH2 produced an important reduction in PHD3 expression, which was reflected 
in a significant induction of HIF-dependent Epo-Luc promoter activity.!SIAH2-3A mutant 
showed a reduced capacity to degrade PHD3, reflected in a lower response to the Epo-
Luc promoter. On the contrary, the phosphomimetic SIAH2-3D mutant showed a 
strongly increased ability to degrade PHD3 and increase the Epo-Luc promoter 
response (Figure 21C). Coexpression of CHK2 strongly diminished PHD3 inhibition by 
SIAH2 and showed a significant reduction in the Epo-Luc promoter response. These 
experiments demonstrate that the SIAH2 phosphorylation mediated by CHK2 can 
regulate its capacity to degrade PHD3. 
 
We subsequently investigated the effects of SIAH2 phosphorylation state in 
response to CHK2 on its capacity to degrade other two relevant SIAH2 substrates as 
DYRK2 and HIPK2. HEK-293T cells were transfected with kinase inactive mutants 
Flag-DYRK2 KD (Figure 22A) or Flag-HIPK2 KD (Figure 22B) in order not to interfere 
with SIAH2 phosphorylation state, together with SIAH2 in the presence or absence of 
full-length CHK2, FHA or SCD domain-deleted mutants. In agreement with the PHD3 
results, the presence of CHK2 significantly reduced HIPK2 and DYRK2 degradation. By 
contrast, FHA or SCD domain-deleted mutants, which lack the ability to phosphorylate 
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SIAH2 (Figure 22C), did not change the levels of both kinases. Altogether these data 
suggest that SIAH2 phosphorylation mediated by CHK2 does not affect its capacity to 
degrade this kinase, but modulates its ability to regulate other substrates such as 
PHD3, DYRK2 and HIPK2. 
 
 
 
Figure 21. The phosphorylation state of SIAH2 does not alter its capacity to degrade 
CHK2. (A) HEK-293T cells were transfected to express Flag-CHK2 or Flag-CHK2 KD (Kinase 
mutant) with increasing amounts of SIAH2, lysed and protein expression was analyzed by 
immunoblot with the indicated antibodies. We show a representative blot of four independent 
experiments. (B) Cells were transfected with Flag-CHK2 and the plasmids encoding SIAH2 wild 
type and the phosphorylation (SIAH2-3A) and the phosphomimic (SIAH2-3D) mutants in the 
residues Thr26, Ser28 and Ser68. After 36 h cells were lysed and the stability of CHK2 was 
revealed by immunoblotting. We show a representative blot of three independent experiments. 
(C) HEK-293T cells were transfected with the indicated plasmids together with a luciferase 
construct controlled by the HIF-1-dependent erythropoietin promoter (Epo-Luc). After 36 h, cells 
were lysed and further analyzed for the indicated proteins by immunoblots (upper panel) or for 
luciferase expression (lower panel). Data are mean ± SD of n = 3 experiments. *** P < 0.001. We 
show a representative blot of three independent experiments.  
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Figure 22. Regulation of SIAH2 activity by CHK2. (A) and (B) HEK-293T cells were 
transfected with the indicated plasmids, and after 36 h lysed and protein expression evaluated by 
immunoblot with the indicated antibodies. We show a representative blot of three independent 
experiments. (C) HEK-293T cells were transfected to express SIAH2 together with different 
amounts of CHK2 wild type or FHA and SCD domain-deleted mutants as indicated. 
Electrophoretic mobility was determined by WB and in parallel SIAH2 phosphorylation was 
analyzed with phospho-specific antibodies for the residues indicated. 
 
 
6.1.6. Effect of SIAH2 on CHK2 capacity to regulate cell cycle arrest or 
apoptosis in response to DNA damage 
 
 CHK2 kinase has a relevant role in the DNA damage response through cell-
cycle checkpoint regulation (Zannini et al., 2014). Therefore, we tested the ability of 
SIAH2 to affect cell-cycle checkpoint activation in response to DNA damage. HEK-293T 
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cells were transfected or not with SIAH2 and treated or not with ETP during 12 hours. 
This time was taken to observe the direct effect on the cell cycle arrest, which was 
analyzed together with the expression of CHK2, CDC25C and SIAH2 proteins. As 
depicted in Figure 23, SIAH2 expression resulted in a clear reversion of the cellular 
arrest in G2/M phase induced by the stimulation with ETP, presenting an inhibition of 
total and phosphorylated CHK2 (Thr68 and Ser516) and a reduction in phospho-
CDC25C-Ser216 protein (CHK2 substrate). 
 
Figure 23. SIAH2 reverts cell cycle arrest caused by DNA damage. HEK-293T cells were 
transfected with increasing amounts of SIAH2 and after 12 h stimulated with ETP (6 µM) during 
12 h. A fraction of the cells was used for cell cycle analysis (left panel) using flow cytometry. Left 
panel shows representative cell cycle distributions. Right panel shows quantitation of 
percentages of the cells in each phase of the cell cycle. Data are mean ± SD of n = 3 
experiments. Another aliquot (lower panel) was lysed and protein expression was analyzed by 
immunoblot with the indicated antibodies. We show a representative blot of three independent 
experiments. 
 
 
 We then investigated whether SIAH2 contributes to the apoptosis induced by 
DNA damage and the CHK2 role on this effect. HeLa cells were transfected with the 
indicated plasmids and stimulated with ETP. As shown in Figure 24A, apoptosis 
percentage induced by stimulation with ETP was reduced in response to SIAH2 
expression. In parallel, a significant reduction in the CHK2 expression was observed. 
Restoration of CHK2 protein expression to its endogenous levels was associated with a 
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significant recovery of apoptosis. Cell cycle phase analysis was performed in parallel 
(Figure 24B).  
 
Figure 24. Role of SIAH2-CHK2 complex in the apoptosis induced by DNA damage. (A) 
HeLa cells were transfected with the indicated plasmids and 24 h later stimulated with ETP (10 
µM) for another 24 h. One aliquot was used for Apoptosis analysis determined by flow cytometry 
using Annexin V/PI Staining (Upper panel), while another fraction was lysed and the levels of the 
indicated protein analyzed by immunoblot. Data are mean ± SD of n = 3 experiments. *** P < 
0.001. (B) HeLa cells were transfected with the indicated plasmids and 24 h later stimulated with 
ETP 10 µM for another 24 h. Cell cycle was analyzed by flow cytometry. Upper panel shows 
representative cell cycle distributions. Lower panel shows quantitation of percentages of the cells 
in each phase of the cell cycle. Data are mean ± SD of n = 3 experiments. 
 
In addition, we observed that SIAH2 expression increases cell viability in 
response to cytotoxic drugs (5-FU or Oxaliplatin) in HEK-293T (Figure 25A) and HeLa 
cells (Figure 25B). Overall, these results indicate the SIAH2 ability to partially regulate 
the CHK2 capacity to control cell cycle arrest or apoptosis in response to DNA damage. 
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Figure 25. Functional consequences of CHK2 regulation by SIAH2. HEK-293T cells (A) and 
HeLa cells (B) were transfected or not to express SIAH2 and 24 h later stimulated as indicated 
with 5-fluorouracil (5-FU, 0.5 µg/ml) or Oxaliplatin (0.5 µM) during 24 h. Cell viability was 
measured by MTT assay. Data are mean ± SD of n = 3 experiments. * P = 0.01; ** P = 0.002; *** 
P < 0.001. (C) HeLa cells were transfected with the indicated siRNA and 24 h later stimulated 
with ETP 10 µM for another 24 h. Cells were subjected to hypoxia (1% O2) during 12 h and one 
fraction was used for apoptosis analysis by Annexin V/PI Staining (Upper panel), while another 
fraction was lysed and the levels of the indicated protein analyzed by immunoblot. Data are mean 
± SD of n = 3 experiments. *** P < 0.001.  
 
Finally, we decided to study the functional consequences of CHK2-SIAH2 
modulation in the context of hypoxia. SIAH2 is an essential component of the hypoxia 
response pathway with relevant implications on the carcinogenesis control (Nakayama 
et al., 2004; Wong and Moller, 2013). Moreover, one of the causes of hypoxic tumor 
resistance to treatment is the hypoxia ability to alter the DNA damage response-
signaling pathway (Bristow and Hill, 2008). To test this hypothesis, we performed 
apoptosis analyses in HeLa cells that were subjected to hypoxia, stimulated with ETP 
and transfected or not with specific siRNA for silencing endogenous SIAH2. Hypoxia 
reduced the percentage of apoptosis in response to ETP, increasing SIAH2 levels and 
significantly reducing CHK2 expression. Moreover, SIAH2 depletion increased CHK2 
levels, which was accompanied by a significant recovery of apoptosis (Figure 25C). 
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Figure 26. Functional consequences of CHK2 regulation by SIAH2 in lung cancer cell lines. 
(A) MOR wt and cisplatin-resistant (CPR) cells or (B) A549 wt and cisplatin-resistant (CPR) cells 
were transfected with SIAH2 or scrambled (control) siRNAs in the absence of cisplatin and after 4 
days were subjected to hypoxia (1% O2) during 12 h as indicated. Cells were lysed and protein 
expression was evaluated by immunoblot with the indicated antibodies.  
 
Similar experiments were performed in A549 and MOR cells where, again, 
hypoxia produced a clear decrease in total and Thr68 CHK2 levels, thereby affecting its 
activity on CDC25C. SIAH2 knockdown under hypoxia conditions produced a significant 
increase in CHK2, which was also reflected in its activity (Figures 26A and 26B). Similar 
results were obtained in the same cisplatin-resistant cell lines, thus indicating that this 
regulation is conserved in at least these two cell types. Collectively, all these results 
conclusively show that hypoxia regulates, at least partially, CHK2 stability and activity 
depending on SIAH2 expression levels. Similarly, they suggest that the resistance to 
apoptosis induced by genotoxic agents in cells subjected to hypoxia is due, at least in 
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part, to the alteration of the DNA damage response-signaling pathway, which can be 
explained as a consequence of CHK2 depletion mediated by the expression of SIAH2. 
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6.2. CDC25A stability is regulated by the kinase DYRK2 
 
6.2.1  CDC25A stability is proteasome and DYRK2 kinase activity 
dependent 
 
In order to identify new DYRK2 substrates implicated in carcinogenesis, we 
performed a kinase array in which 1024 peptides were incubated with recombinant 
DYRK2 active protein in vitro (data not shown). The phosphatase CDC25A was found 
within the top 30 of the positive results in our screening. Given its essential role as a 
key regulator of the cell-cycle progression, we focused in studying in detail the effect of 
DYRK2 on CDC25A.  
 
To study this effect, we first co-expressed CDC25A alone or in the presence of 
DYRK2 in HEK-293T cells. As shown in Figure 27A, protein levels of the phosphatase 
were reduced in the presence of increasing amounts of DYRK2. Similar results were 
obtained at endogenous levels when HeLa cells were transfected with increasing 
amounts of DYRK2, without affecting its mRNA expression (Figure 27B). Then we 
analyzed the effect of DYRK2 inhibition by siRNA on CDC25A expression (Figure 27C). 
DYRK2 depletion substantially increased CDC25A levels, indicating an inverse 
correlation between the expression of these two proteins. Taken together, these results 
suggest that DYRK2 regulates CDC25A turnover through a mechanism occurring at the 
protein level affecting its stability. 
 
As CDC25A regulation by kinases is often accompanied by a proteasome 
dependent degradation (Busino et al., 2004), we decided to analyze the role of this 
relevant mechanism in the case of DYRK2. We co-expressed CDC25A with increasing 
amounts of DYRK2 in the presence or absence of the proteasome inhibitor MG-132. As 
shown in Figure 28A, the reduction of the ectopic levels of CDC25A in response to 
DYRK2 was restored when cells were treated with MG-132. 
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Figure 27. DYRK2 expression affects the stability of CDC25A. (A) HEK-293T cells were 
transfected with expression plasmids encoding Flag-CDC25A and Myc-DYRK2 as indicated. 48 h 
after transfection, cells were lysed and protein expression analyzed by immunoblot. We show a 
representative blot of three independent experiments. (B) HeLa cells were transfected to express 
increasing amounts of DYRK2, harvested and lysed. One fraction was used to analyze 
endogenous CDC25A protein levels while another aliquot was used to analyze CDC25A mRNA 
levels by qPCR. Data are mean ± SD of n = 3. We show a representative blot of three 
independent experiments. (C) HEK-293T cells were transfected with DYRK2 or scrambled 
(control) siRNAs, lysed after 4 days of culture and DYRK2 and CDC25A endogenous levels were 
analyzed by WB. We show a representative blot of three independent experiments. 
 
 
 
Next, we decided to analyze the impact of DYRK2 kinase activity on CDC25A 
stability. DYRK2-wt overexpression was able to diminish the protein levels of CDC25A, 
an effect not observed with DYRK2 kinase dead mutant (KD) (Figure 28B). Moreover, 
we studied the effect of DYRK2 expression over CDC25A half-life. DYRK2-wt 
overexpression decreased the half-life of ectopic CDC25A, what did not occur in the 
presence of DYRK2-KD (Figure 29A). On the other hand, the half-life of endogenous 
CDC25A was prolonged under the knockdown of DYRK2 by specific siRNA (Figure 
29B). Altogether, these results demonstrate that DYRK2 negatively regulates CDC25A 
expression through an ubiquitin/proteasome and DYRK2 kinase activity dependent 
process, as well as CDC25A basal levels are modulated according to DYRK2 
expression. 
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Figure 28. CDC25A degradation by DYRK2 is proteasome and DYRK2 kinase activity 
dependent. (A) HEK-293T cells were transfected with expression plasmids encoding Flag-
CDC25A and Myc-DYRK2 and after 36 h the proteasome inhibitor MG-132 (10 µM) was added 
for another 12 h at the indicated points. Protein levels were analyzed by WB. (B) Cells were 
transfected with Flag-CDC25A together with Myc-DYRK2 wt (wild type) or KD (kinase death). 
Proteins were subjected to WB analysis with the indicated antibodies. We show a representative 
blot of three independent experiments.  
 
 
 
 
Figure 29. CDC25A half-life changes according to DYRK2 levels. (A) HEK-293T cells were 
transfected with CDC25A and DYRK2-wt or DYRK2-KD as indicated and after 36 h, treated with 
the protein synthesis inhibitor cycloheximide (CHX) (100 μg/ml) for 3 and 6 h. Cell lysates were 
analyzed by immunoblot using actin expression as the loading control. The graph represents the 
mean ± SD of band density from 3 different experiments. (B) Cells were transfected with either 
DYRK2 or scrambled (control) siRNAs and, after 4 days of culture, were incubated with CHX (100 
μg/ml) during 30, 60 and 90 min. Cell lysates were analyzed by WB with the indicated antibodies. 
The graph represents the mean ± SD of band density from 3 different experiments. 
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6.2.2. CDC25A degradation is exclusive of DYRK subfamily 
 
As mentioned before, DYRK2 belongs to the DYRK subfamily of protein 
kinases (Aranda et al., 2011). To test the ability of the rest of the members of this 
subfamily to affect CDC25A stability, HEK-293T cells were transfected to express 
CDC25A and the members of human DYRK subfamily (DYRK1A, DYRK1B, DYRK2, 
DYRK3, and DYRK4). As shown in Figure 30, DYRK1B and DYRK2 overexpression 
resulted in a clear decrease of CDC25A protein levels, which was not observed in the 
case of DYRK1A, DYRK3 or DYRK4. 
 
Figure 30. Effect of DYRK subfamily on CDC25A stability. HEK-293T cells were transfected 
to express the indicated combination of proteins. After 48 h, cells were lysed and protein 
expression was evaluated by immunoblot with the indicated antibodies. The positions and 
molecular weights (in kDa) are indicated. We show a representative blot of three independent 
experiments. 
 
In the same sense, DYRK2 is highly related with HIPK2, other member of the 
DYRK family with which it shares some substrates like p53 (Puca et al., 2010; Taira et 
al., 2007) or SIAH2 (Calzado et al., 2009; Perez et al., 2012). Therefore, we decided to 
evaluate the HIPK2 capacity to control CDC25A stability. Strikingly, HIPK2 
overexpression increased ectopic CDC25A levels, being this effect HIPK2 kinase 
activity independent (Figure 31A). Next, we studied the role of HIPK2 on the effect of 
DNA damage over CDC25A and DYRK2 using HIPK2-/- and WT cells. Adriamycin 
treatment decreased substantially CDC25A levels and induced DYRK2 ones in both 
HIPK2-/- and WT cells (Figure 31B) without significant difference. Collectively, these 
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data show that CDC25A degradation is exclusive of DYRK subfamily, being DYRK2 the 
most effective in degrading the phosphatase among its members. 
 
 
Figure 31. Role of HIPK2 on CDC25A degradation by DYRK2. (A) HEK-293T cells were 
transfected with the indicated plasmids. After 48 h, cells were lysed and proteins were subjected 
to WB analyses with the indicated antibodies. (B) HEK-293T WT and HEK-293T HIPK2-/- cells 
were treated with Adriamycin (ADR) (6 µM) during 24 h. Cells were lysed and protein expression 
was evaluated by WB using DYRK2 and CDC25A antibodies. We show a representative blot of 
three independent experiments. 
 
 
6.2.3. DYRK2 phosphorylates CDC25A in vitro 
 
To investigate whether DYRK2 directly phosphorylates CDC25A, we carried out 
in vitro phosphorylation analyses. First, we performed an in vitro kinase assay. 
Increasing amounts of recombinant DYRK2 resulted in the appearance of upper bands 
of recombinant CDC25A, corresponding to phosphorylated forms of the phosphatase 
as they were detected with a specific phospho-S/T-Pro antibody. Regarding DYRK2, 
the presence of CDC25A led to a faster migrated form of the kinase observed on SDS-
PAGE (Figure 32A). To extend this finding further, recombinant CDC25A was incubated 
in the presence or absence of GST-DYRK2 forms (WT and KD). CDC25A 
phosphorylation was only detected by autoradiography when GST-DYRK2-wt was 
present (Figure 32B). 
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Figure 32. CDC25A is phosphorylated in vitro by DYRK2. (A) In vitro kinase assay was 
performed with active DYRK2 and CDC25A recombinant proteins. CDC25A phosphorylation was 
determined with phospho-S/T-Pro antibody, while total protein levels of DYRK2 and CDC25A 
were recognized by its specific antibodies. (B) Active CDC25A recombinant protein was 
incubated with GST-DYRK2-wt, GST-DYRK2-KD or GST alone. Phosphorylation was determined 
by autoradiography, while protein levels of CDC25A were detected by WB. 
 
It is widely described that CDC25A degradation by the proteasome is mainly 
regulated by SCFβTRCP and APC/C ubiquitin-ligase complexes (Busino et al., 2004; 
Busino et al., 2003; Donzelli et al., 2002), which need to recognize specific residues 
phosphorylated within the DSG motif or bind to KEN motif, respectively, in order to 
accomplish the degradation of the phosphatase. Given that DYRK2 promotes CDC25A 
degradation by the proteasome (Figure 28A), we generated CDC25A DSG and KEN 
mutants (Figure 33A) to study whether these motifs were implicated in the process. 
Particularly, within DSG motif, Ser88, but not Ser82, is followed by a proline. Bearing in 
mind that DYRK2 has a preference for phosphorylating serines followed by proline    
(DYRK2 consensus: R/K X X (X) S/T P/V), we mutated Ser88 to alanine to generate the 
DSG mutant. HEK-293T cells were transfected with CDC25A WT or mutants forms 
together or not with DYRK2. Surprisingly, DYRK2 degraded similarly either CDC25A 
WT or CDC25A mutants (Figure 33B). All these results clearly indicate that DYRK2 
directly phosphorylates CDC25A in vitro, although DSG or KEN motifs are not involved 
in the CDC25A degradation by the proteasome mediated by DYRK2. 
 
Since DYRK2 directly phosphorylates CDC25A, it is reasonable to consider that 
both proteins are interaction partners. To test this hypothesis, we performed different 
methodological approximations including co-immunoprecipitation assays but, 
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unfortunately, we were unable to pull down the phosphatase together with DYRK2 or 
vice versa (data not shown).  
 
 
Figure 33. DSG or KEN motifs are not involved in the CDC25A degradation by DYRK2. (A) 
Schematic representation of CDC25A-wt and its mutants (S88 àA88 (S88A) within DSG motif; 
KEN motif deletion (DKEN); double mutant (S88A + DKEN)). (B) HEK-293T cells were transfected 
with CDC25A-wt or CDC25A mutants together or not with GFP-DYRK2. Cell lysates were 
analyzed by WB with the indicated antibodies. We show a representative blot of three 
independent experiments. 
 
 
6.2.4. DYRK2-CDC25A protein levels correlation under different stimuli 
 
Given the fact that we were unable to detect a direct DYRK2-CDC25A complex, 
we could not rule out the possibility of the existence of intermediate partners between 
both proteins. We examined whether proteins belonging to the ATM/ATR DNA damage 
pathway or some phosphatases were playing a role in the CDC25A regulation by 
DYRK2. No differences were observed on CDC25A degradation performed by DYRK2 
when cells were incubated with Caffeine, an ATM/ATR inhibitor (Figure 34A), or 
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Calyculin A, a phosphatase inhibitor (Figure 34B) compared with control ones. These 
data indicate that CDC25A degradation by DYRK2 is ATM/ATR and phosphatases 
independent. 
 
Figure 34. DYRK2 effect over CDC25A is phosphatase and ATM/ATR independent. (A) 
HEK-293T cells were transfected to express the indicated combination of proteins. After 48 h, 
cells were incubated with Caffeine (3 mM) during 3 h as shown. Cell lysates were analyzed by 
WB with the indicated antibodies. We show a representative blot of three independent 
experiments. (B) HEK-293T cells were co-transfected to express CDC25A and DYRK2 at the 
indicated points. 48 h after transfection, Calyculin A (100 nM) was added for another 30 min as 
indicated.  Cells were lysed and protein expression analyzed by immunoblotting.  
 
DYRK2 protein expression variations under different stimuli have been reported 
previously (Guo et al., 2016; Zhang et al., 2016). To evaluate the behavior of the 
phosphatase under these conditions, several cell lines were subjected to serum 
starvation or DNA damage. When cells were serum starved (synchronized at G1) and 
then released, it was observed a clear relation between DYRK2 and CDC25A protein 
levels H727 cells (Figure 35A). Similar results were obtained after double thymidine 
synchronization of HeLa cells in concrete phases of the cell cycle, specifically at G2/M 
(Figure 35B). Furthermore, ADR treatment increased DYRK2 expression levels in HEK-
293T cells, what resulted in a reduction of CDC25A that was restored in part by DYRK2 
specific siRNA silencing (Figure 35C). In MOR cells, an ADR dose dependent DYRK2 
stabilization accompanied by a CDC25A inhibition was detected (Figure 35D). These 
experiments demonstrate that an inverse correlation exists between both proteins in 
response to different stimuli.  
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Figure 35. DYRK2-CDC25A protein levels correlation under different stimuli. (A) H727 cells 
were serum starved for 48 h (synchronized at G1) and then released (serum stimulation) for 0, 4, 
8, 12, or 24 h (entered into the cell cycle). Protein fraction was subjected to WB analyses with the 
indicated antibodies. (B) HeLa cells were synchronized by double-thymidine block, then released 
into fresh media and harvested after 0 (G1 fraction), 3.5 (S fraction), 6 (G2 fraction) and 10 h (M 
fraction); A = asyncronized control cells. Cell cycle was analyzed by PI staining and flow 
cytometry (left panel). The expression of DYRK2 and CDC25A proteins evaluated in parallel by 
WB (right panel). (C) HEK-293T cells were transfected with DYRK2 or scrambled (control) 
siRNAs and after 3 days incubated with ADR (6 µM) for another 24 h. Cells were lysed and 
protein expression analyzed by immunoblot. (D) MOR cells were stimulated with increasing ADR 
concentrations (1, 2, 4 and 6 µM) during 24 h. Cell lysates were analyzed by WB with the 
indicated antibodies. We show a representative blot of three independent experiments. 
 
 
6.2.5. Correlation of DYRK2 and CDC25A in human lung cancer cells 
(HLCC) 
 
It has been previously described an important role of DYRK2 in pulmonary 
carcinogenesis (Miller et al., 2003), together with increased expression of CDC25A 
(Boutros et al., 2007). Based on this and other evidences, we decided to evaluate the 
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relation between CDC25A and DYRK2 in different human lung cancer cell lines. First, 
we studied endogenous levels of both proteins in the BEAS-2B model, in which human 
bronchial epithelial cells undergo squamous differentiation in response to serum (Figure 
36A). This model helps us to better understand the carcinogenesis process in lung 
cancer. Corroborating previous results, this model showed us an inverse correlation 
between DYRK2 and CDC25A. Moreover, the more differentiated the cells are, a higher 
phosphatase expression and a lower kinase expression was observed (Figure 36B). 
This correlation was also confirmed at endogenous levels in other lung cancer cells, 
such as A549 and H727 (Figure 36B).  
 
 
Figure 36. Expression and correlation between DYRK2 and CDC25A in HLCC. (A) Illustrative 
images of BEAS-2B differentiation model, in which human bronchial epithelial cells (BEAS-2B; 
left panel) undergo squamous differentiation in response to serum (right panel). (B) Different 
HLCC were lysed and the protein fraction was analyzed by WB with specific DYRK2 and 
CDC25A antibodies. We show a representative blot of three independent experiments. 
 
 
Next, differentiated BEAS-2B cells were transfected to express DYRK2-wt or 
DYRK2-KD (in the presence or absence of MG-132). Ectopic and endogenous 
CDC25A levels were analyzed under these conditions. The results demonstrated that 
DYRK2 overexpression degraded CDC25A at both ectopic (Figure 37A) and 
endogenous levels (Figures 37B). Likewise, ectopic CDC25A degradation by DYRK2 
was also observed in H727 cells (Figure 37C). Once again, this degradation was 
noticed to be proteasome and DYRK2 kinase activity dependent. Taken together, these 
results confirm our biochemical model of CDC25A regulation by DYRK2 in lung cancer 
cell lines. 
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Figure 37. CDC25A degradation by DYRK2 in HLCC. Differentiated BEAS-2B (A) and H727 
cells (C) were co-transfected to express CDC25A together with DYRK2-wt or DYRK2-KD (in the 
presence or absence of MG-132). Cell lysates were analyzed by WB with the indicated 
antibodies. (B) Differentiated BEAS-2B cells were transfected with Myc-DYRK2-wt or Myc-
DYRK2-KD (in the presence or absence of MG-132). Cells were lysed and protein expression 
analyzed by immunoblot. We show a representative blot of three independent experiments. 
 
 
6.2.6. DYRK2 and CDC25A expression in human lung cancer tissue 
 
We have previously demonstrate the significant decrease in DYRK2 expression 
in samples of patients with lung cancer (adenocarcinoma and squamous) compared to 
their corresponding healthy ones by immunohistochemistry (IHC) (Moreno et al., 2015). 
We then decided to correlate this outcome with published CDC25A expression data in 
human lung cancer tissues. In contrast to DYRK2, CDC25A expression is increased in 
adenocarcinoma and squamous lung cancer tissues (Protein Atlas) (Figure 38A). 
Moreover, comparison of reported DYRK2 and CDC25A protein expression levels in a 
variety of tumors reveals an inverse correlation between them, with the exception of 
melanoma and endometrial, testis and prostate cancers (Figure 38B). Once more, it is 
observed an inverse correlation of the protein expression of DYRK2 and CDC25A in 
tumors, including lung cancer, that confirm and validate our previous results. 
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Figure 38. Correlation of DYRK2 and CDC25A expression in human lung cancer tissue. (A) 
Representative images of adenocarcinoma or squamous cell carcinoma stained with DYRK2 
antibody (adapted from Moreno et al, 2015) or CDC25A antibody (adapted from Protein Atlas) 
(x100). (B) Comparative study of reported DYRK2 and CDC25A protein expression levels in a 
wide range of tumors (adapted from Protein Atlas). 
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7.1. CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2 
 
The ubiquitin-proteasome pathway is critical for the expression and activity 
control of proteins implicated in cell cycle control and DNA damage response	 (Kirkin & 
Dikic, 2011; Liu et al., 2014). CHK2 is a stable protein with a 6-hour half-life whose 
regulation and degradation mechanisms in the absence of DNA damage are not 
completely known	 (Lukas et al., 2001; Zannini et al., 2014). Although the 
phosphorylation levels and the action of several phosphatases are the most relevant 
mechanism to keep CHK2 inactive,	 (Carlessi et al., 2010; Freeman et al., 2010; 
Fujimoto et al., 2006)	 different evidences suggest the role of ubiquitination to control the 
stability of this kinase. Firstly, the capacity of Ub E3 ligase Mdm2 and acetyltransferase 
PCAF to increase CHK2 ubiquitination has been described, but in an independent way 
to their E3 ligase activities	 (Kass et al., 2009). Similarly, the role of EDD in CHK2 
activation has been reported, although its ability to mediate CHK2 ubiquitination has not 
been demostrated yet	 (Munoz et al., 2007). Recently, the ability of the E3 ligase RNF8 
in human, and PIRH2 in mice	 to ubiquitylate and degrade CHK2 has been 
characterized (Bohgaki et al., 2013; Feng & Chen, 2012). It should be underlined that, 
whereas these two E3 ligases mediate degradation in response to DNA damage, our 
results suggest that SIAH2 regulates CHK2 basal expression. 
 
 In the present work we describe the capacity of CHK2 to directly interact in vivo 
with SIAH2, mainly colocalizing in the nucleus. Through different experimental 
approaches, we prove that SIAH2 mediates CHK2 ubiquitination and proteosomal 
degradation. SIAH2 depletion increases CHK2 levels, thereby supporting our 
observation that SIAH2-deficient cells show high CHK2 levels. Phosphorylation in 
S456, which has been proved to be critical for CHK2 ubiquitination, is not here relevant 
for CHK2 degradation	 (Kass et al., 2007). Similarly, our results show that SIAH2-
mediated CHK2 degradation is independent of both phosphorylation in T68 and its 
kinase activity. Likewise, DNA damage alters the interaction between both proteins, 
thus decreasing SIAH2-mediated CHK2 levels and not affecting the endogenous levels 
of CHK2 T68 or S516. These results suggest that SIAH2 interacts and regulates a pool 
of CHK2 in the absence of stimuli. In response to DNA damage, a CHK2 fraction would 
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split from SIAH2, thus avoiding its degradation and allowing its stabilization. Although 
the exact mechanism underlying the separation of SIAH2 from CHK2 after DNA 
damage is unknown, it seems reasonable to think that it could be the result of post-
transductional modifications suffered by any of the two proteins in response to this 
stimulus. The absence of a complete dissociation of both proteins in response to DNA 
damage observed in our results could explain the existence of different CHK2 fractions 
controlled by SIAH2 contributing to the cell cycle control (Figure 27). 
 
 The regulation of ubiquitin ligases activity is critical for the control of its 
substrates. Different control mechanisms have been described for SIAH family, 
amongst which the role of phosphorylation stands out	 (Knauer et al., 2015).	 Others and 
we have reported that SIAH2 phosphorylation affects its activity, and three kinases with 
SIAH2 as substrate have been described so far	 (Calzado et al., 2009; Khurana et al., 
2006; Perez et al., 2012). In this work we also highlight CHK2 capacity to phosphorylate 
SIAH2 in at least three residues, not affecting its activity on this kinase, but decreasing 
its ability to degrade other substrates. These results are consistent with previous 
reports describing how SIAH2 phosphorylation modulates its activity specifically on 
certain substrates	 (House et al., 2009; Perez et al., 2012; Winter et al., 2008). Similarly, 
our results show how ETP stimulation significantly reduces CHK2-mediated SIAH2 
phosphorylation, in agreement with the loss of interaction between these two proteins. 
As a consequence, the activity of SIAH2 on some of its substrates in response to DNA 
damage would be modified. The changes observed in some SIAH2 substrates in 
response to DNA damage such as DYRK2 are in accord with this hypothesis	 (Taira et 
al., 2007; Taira et al., 2010). 
 
 From the functional point of view, CHK2 plays a relevant role in the cell cycle 
control in response to DNA damage, inhibiting CDC25C phosphatase through Ser216 
phosphorylation and avoiding mitosis	 (Bulavin et al., 2003; Zannini et al., 2014). Our 
results demostrate how SIAH2 expression resulted in a clear reversion of cellular arrest 
induced by ETP stimulation. Besides, we demonstrate that the loss of SIAH2-mediated 
CHK2 partially prevented ETP-induced apoptosis en HeLa cells, which was recovered 
by returning CHK2 protein expression to endogenous levels. These data prove that 
 Discussion 
 
	 93 
SIAH2 expression affects cell cycle activation checkpoints through the control of CHK2 
levels. 
 Finally, many studies support the concept that hypoxia is directly implicated in 
tumor progression and metastasis, mediating apoptosis resistance and reducing the 
ability to repair DNA	 (Bristow & Hill, 2008; Wilson & Hay, 2011). Different works have 
reported how intratumoral hypoxia significantly modifies the action of some drugs and 
promotes metastasis	 (Frankenberg-Schwager et al., 1991; Wilson & Hay, 2011). 
Similarly, cells subjected to hypoxia present a lower capacity to repair DNA and, as a 
consequence, they become more resistant to chemotherapy	 (Blais et al., 2006; Terris et 
al., 2002). Different clinical trials that attempted to diminish tumor hypoxia have 
significantly improved cell sensibility to radiotherapy and chemotherapy, which resulted 
in a higher rate of survival	 (Overgaard, 2007). In general, the concept that hypoxia 
increases cell resistance to apoptosis through different mechanisms is consistent with 
our results. SIAH2 has the capacity to regulate HIF-1a levels, and thus the 
physiological response to hypoxia	 (Nakayama et al., 2004). We observed that hypoxia 
decreases CHK2 levels, parallel to an increase of both SIAH2 and cell resistance to 
apoptosis induced by ETP. We have also observed how SIAH2 expression increases 
cell viability in response to cytotoxic drugs such as 5-FU or Oxaliplatin. These data are 
equally supported, at least partially, by previous results which also showed lower CHK2 
levels under hypoxia in HeLa and MCF-7 cells	 (Gibson et al., 2005). Altogether, this 
finding suggests a new action mechanism by which hypoxia may alter DNA damage-
response pathway via SIAH2-CHK2 modulation. 
 
 In summary, our results indicate that E3 Ubiquitin ligase SIAH2 regulates CHK2 
basal turnover. Additionally, CHK2 presents the ability to phosphorylate SIAH2, 
affecting its activity on certain substrates. In response to DNA damage, the interaction 
between both proteins is altered, which favors CHK2 stabilization. We propose that this 
new CHK2 regulation mechanism has an influence on cell cycle control and on the 
ability of hypoxia to alter DNA damage-response pathway in cancer cells. Further 
studies of the relationship of these two proteins in tumors are needed to support this 
hypothesis. 
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Figure 39. Schematic model for the ability of SIAH2 to regulate CHK2 by ubiquitination. 
Under normal conditions SIAH2 is able to interact and modulate the basal turnover of CHK2 by 
ubiquitination and proteasome degradation. Simultaneously, CHK2 is able to phosphorylate 
SIAH2 in at least three residues (Thr26, Ser28 and Ser68). The DNA-damage response causes 
alteration in the protein-protein interaction, promoting CHK2 stabilization and SIAH2 activity 
modification. 
 
 
7.2. CDC25A stability is regulated by the kinase DYRK2 
 
Due to its major function as key controller of normal cell division and mediator 
of the checkpoint response to DNA damage, CDC25A regulation results essential for 
the proper cell division. One of the most studied post-translational mechanisms of 
CDC25A regulation is its degradation through the	 ubiquitin–proteasome pathway 
(Busino et al., 2004), mainly mediated by SCFβTRCP and APC/CCdh1 ubiquitin-ligase 
complexes (Busino et al., 2003; Donzelli et al., 2002). For that purpose, in the majority 
of cases, CDC25A is required to be previously phosphorylated in specific residues. The 
kinases described to date able to achieve that task are CHK1 and CHK2, p38, CK1A 
and NEK11 (Boutros et al., 2007; Busino et al., 2004; Honaker & Piwnica-Worms, 2010; 
Melixetian et al., 2009), that seems to be a reduced number of CDC25A regulators 
given the relevant function of the phosphatase, what in turn indicates that more kinases 
could be involved in the mechanism. Here we describe a new kinase able to mediate 
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post-translational regulation of CDC25A. DYRK2 negatively regulates CDC25A 
expression through an ubiquitin/proteasome and DYRK2 kinase activity dependent 
process, resulting in a significant reduction of its half-life. At first instance our results 
indicate that CDC25A degradation by DYRK2 is ATM/ATR pathway independent, 
suggesting that DYRK2 regulates the basal turnover of CDC25A, and therefore being 
involved in the normal control of cell cycle but not in the regulation of the phosphatase 
in response to DNA damage. Nevertheless, we have observed that the reduction of 
CDC25A under the DNA damage agent ADR is restored in part by DYRK2 specific 
siRNA silencing. Likewise, the ADR dose dependent DYRK2 stabilization is 
accompanied by a CDC25A inhibition. Thus, we can not rule out that DYRK2 could be 
also taking part in CDC25A regulation under DNA damage. These results may arise the 
possibility of a dual role of DYRK2 in regulating CDC25A expression, both under normal 
conditions and under DNA damage, as it occurs in the case of CHK1, CHK2 or p38 
(Boutros et al., 2006; Busino et al., 2004).   
 
Although DYRK2 is the most effective in degrading CDC25A among the 
members of DYRK subfamily, we observed that the presence of DYRK1B also had a 
role regarding the phosphatase degradation. Besides DYRK1B and DYRK2 belong to 
different groups within the DYRK subfamily (class I and class II, respectively), it 
appears that they have similar functions concerning other substrates, as it has also 
been proved by us (Perez et al., 2012) and various colleagues (unpublished data). On 
the other hand, DYRK2 shares some substrates with its highly related HIPK2 kinase, 
such as p53 (Puca et al., 2010; Taira et al., 2007) or SIAH2 (Calzado et al., 2009; 
Perez et al., 2012). In the case of CDC25A, HIPK2 does not degrade the phosphatase 
but increases its protein levels (both wt and KD forms of the kinase), without interfering 
with CDC25A degradation by DYRK2.  
 
In order to go further in examining the possible sites for DYRK2 
phosphorylation on the phosphatase, we generated CDC25A DSG and KEN motifs 
mutants, given that they are needed for SCFβTRCP and APC/C mediated-CDC25A 
proteasome degradation, respectively (Busino et al., 2004; Busino et al., 2003; Donzelli 
et al., 2002). Furthermore, a recent study revealed that SCFβTRCP is responsible of 
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DYRK1A proteasome degradation, what results essential for cell cycle progression (Liu 
et al., 2016). The fact that DYRK1A is related to SCFβTRC, reinforced our hypothesis of 
the implication of this complex in DYRK2-CDC25A regulation. However and unexpected 
for us, DYRK2 expression degraded similarly either CDC25A WT or CDC25A DSG and 
KEN mutants, indicating that DYRK2-mediated proteasome degradation of the 
phosphatase may not be occurring via the classical ubiquitin-proteasome pathways 
described for it. On the other hand, the process could be taking place via an alternative 
ubiquitin pathway, like the DYRK2-related SCFFbw7 or EDVP (Jung et al., 2013; Maddika 
& Chen, 2009) or the CDC25A-related Cul4B-DDB1DCAF8 (Wu et al., 2016), or even 
unidentified ones, thus opening up a new horizon in this field.  
 
It is a fact that fluctuations in CDC25A protein levels exist during the cell cycle, 
being a result from an exhaustive regulation by periodic synthesis and by ubiquitin 
mediated proteolysis.! At the end of mitosis and during G1, CDC25A protein levels are 
kept low by APC/CCdh1, after what they are increased because of the requirement of 
the phosphatase for G1/S transition. During S and G2 phases, CDC25A levels are 
regulated by SCFβTCRP-dependent turnover and finally, over mitosis CDC25A is 
stabilized by Cyclin B/CDK1 phosphorylation on Ser18 and S116, which acts as a 
positive-feedback mechanism for Cyclin B/CDK1 activation, and therefore, allowing G2-
M transition of the cells (Hayes & Harper, 2010). Our results regarding CDC25A 
expression levels that arise from HeLa cell cycle analyses are consistent with these 
previous published data. In terms of DYRK2 expression during cell cycle, it has been 
reported its upregulation at the start of S phase that persists, but decreasing slightly, 
throughout G2 and M phases in HaCat cells (Guo & Dixon, 2016; Guo et al., 2016).!Our 
data is in concordance with that observation, since we also observe in HeLa cells a 
markedly overexpression of DYRK2 in S and G2 phases that is not maintained at those 
levels during mitosis. Moreover, these cell cycle analyses show us a clear relation 
between DYRK2 and CDC25A expression levels at two specific phases of the cell 
cycle: G2 and M. This outcome suggests a probably specific role of DYRK2 over 
CDC25A during G2 and/or M phases, could being influenced by DYRK2 expression 
levels and/or by its activity. Further studies are needed to achieve a complete 
understanding of this mechanism. 
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Over the last decade, it has been enhanced the evidence of the engagement of 
DYRK2 in proper control for cell division, through the phosphorylation and consequent 
degradation of diverse substrates including c-Jun/c-Myc, Tert and Kataninp60 (Nihira & 
Yoshida, 2015). Most importantly, DYRK2 functions as a priming kinase for GSK3 and 
the SCFFbw7 complex in G1 phase, because c-Jun and c-Myc degradation is essential 
for G1/S transition (Taira et al., 2012). However, DYRK2 binds to the EDVP complex 
and triggers proteasomal degradation of TERT (Jung et al., 2013) and Katanin p60 
(Maddika & Chen, 2009) in G2/M phase. More recently it has been described that 
DYRK2 phosphorylates Rpt3 (proteasome subunit) at Thr25 in a cell cycle-dependent 
manner,! mainly during S and G2/M phases (Guo & Dixon, 2016). Because 
dysregulation of cell cycle progression leads to tumorigenesis, DYRK2 might have a 
tumor suppressive role in cancer cells. According to these data, here we have proved 
that DYRK2 directly phosphorylates the checkpoint phosphatase CDC25A in vitro, 
increasing this way the list of DYRK2 substrates that are involved in the control of the 
cell cycle. As mentioned above, further research is needed to elucidate the role of 
DYRK2 over CDC25A in the different phases of the cell cycle.  While it is true that we 
were not able to pull down both proteins together, it does not mean that they are not 
interaction partners. Sometimes the interaction between kinase and substrate is real 
ephemeral and short lived, thus hampering its detection by experimental approaches. 
Moreover, we need to keep in mind that DYRK2 could be degrading CDC25A as a part 
of a complex (such as previous mentioned SCFFbw7 or EDVP), what may difficult this 
observation as well.  
 
Despite there are some studies that have reported a high DYRK2 expression in 
esophagus and lung cancers and neuroblastoma (Miller et al., 2003; Park et al., 2002; 
Varjosalo et al., 2008), in general, it has been described a reduced or abolished DYRK2 
expression in multiple human tumor tissues, including kidney, lung, breast, colon, 
prostate, esophagus, bladder and hepatocarcinoma. In most of them the low DYRK2 
expression correlates with shorter survival (Yamashita et al., 2009), invasiveness (Taira 
et al., 2012), cancer recurrence (Enomoto et al., 2014) or poor prognosis  (Yan et al., 
2016). Moreover, DYRK2 has been also proposed as potential prognostic marker for 
cancer and metastasis (Nomura et al., 2015) and as predictive marker for clinical 
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responses to cancer treatment (Mimoto et al., 2017). These data shows that a lack of 
DYRK2 expression leads to cancer development in a wide range of tissues, supporting 
the role of DYRK2 as a tumor suppressor. Therefore, up-regulation of DYRK2 
expression or activity in that tissues might be a useful strategy for cancer prevention 
(Nihira & Yoshida, 2015). 
 
In contrast with the above, CDC25A is considered an oncogene since it is 
highly overexpressed in most cancer tissues, where accelerates the G1/S and G2/M 
transitions, leading to genomic instability and being responsible for tumorigenesis 
promotion. CDC25A has been reported to be overexpressed in various human cancers, 
including breast, colorectal, lung pancreas, hepatocellular, thyroid and non-Hodgkin 
lymphoma among others, being highly associated a shorter disease-free survival, 
malignancy and poor prognosis in cancer patients (Boutros et al., 2007; Kristjansdottir 
& Rudolph, 2004). Consequently, CDC25A inhibition is considered as a potential 
therapeutic target against cancer, but unfortunately to date there is no specific inhibitors 
of CDC25A, since the ones available show cross-reaction with the three CDC25 
isoforms (Brenner et al., 2014). 
 
In summary, in the present work we describe the capacity of DYRK2 to negatively 
regulates the checkpoint phosphatase CDC25A expression through an 
ubiquitin/proteasome and kinase activity dependent process. As well, we demonstrate 
that DYRK2 is capable to directly phosphorylate the phosphatase in vitro. Different 
stimuli, such as DNA damage or serum starvation, result in an inverse correlation of 
DYRK2 and CDC25A expression, which is also observed at endogenous levels in 
human lung cancer cell lines and human lung cancer tissues (Figure 40). 
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Figure 40. Schematic model for the ability of DYRK2 to regulate CDC25A. DYRK2 is able to 
modulate the basal turnover of CDC25A by phosphorylation and proteasome degradation (left 
panel). We report the existence of an inverse correlation of DYRK2 and CDC25A expression 
levels in lung cancer cell lines as well as in human tumors of the lung (right panel). 
Chemotherapeutics drugs switch this correlation the other way around.  
 
Taken together, our findings report new substrates (SIAH2 and CDC25A) for 
two relevant kinases involved in the DNA Damage Response pathway (CHK2 and 
DYRK2), helping to elucidate the molecular mechanisms through which this pathway 
operates. A deeper understanding of the regulation mechanisms of these relevant 
kinases will extend the knowledge about the molecular biology of cancer as well as 
provide new therapeutic opportunities for cancer treatment. Additionally, examining the 
collateral genomic damage caused by DNA repair deficiency could provide biomarkers 
to aid in the selection of cancer therapy, not only predicting the sensitivity of DNA 
damaging agents that maximize cytotoxicity for cancer cells, but also determining the 
proper dosing of DNA damage drugs to minimize the side effect for normal cells. This 
way, personalized cancer treatments would be achieved.  
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1. It exists a direct physical interaction between CHK2 and the E3 Ubiquitin ligase 
SIAH2, being several domains responsible for binding in both proteins. CHK2-
SIAH2 complex is partially disrupted in response to DNA damage without impairing 
its subcellular co-localization, but favoring CHK2 stabilization. 
 
2. CHK2 presents the ability to directly phosphorylate SIAH2 at a minimum of three 
residues, without affecting its capacity to degrade this kinase but modulating its 
activity on other substrates such as PHD3, DYRK2 and HIPK2. 
 
3. SIAH2, in turn, is capable to regulate the basal turnover of CHK2, through a SIAH2-
mediated ubiquitination and proteasomal degradation occurring at the protein level, 
affecting its stability and activity. 
 
4. CHK2 regulation by SIAH2 has an influence on cell cycle control and on the ability 
of hypoxia to alter DNA damage-response pathway in cancer cells. 
 
5. DYRK2 negatively regulates the checkpoint phosphatase CDC25A expression 
through an ubiquitin/proteasome and DYRK2 kinase activity dependent process, 
affecting its half-life.  
 
6. DYRK2 is the most effective in degrading the phosphatase among the members of 
its subfamily. CDC25A degradation by DYRK2 is not influence by HIPK2. 
 
7. DYRK2 directly phosphorylates CDC25A in vitro. DSG or KEN motifs of CDC25A 
are not involved in the proteasome degradation mediated by DYRK2. 
 
8. Different stimuli, such as DNA damage or serum starvation, result in an inverse 
correlation of DYRK2 and CDC25A expression, which is also observed at 
endogenous levels in human lung cancer cell lines and human lung cancer tissues. 
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ORIGINAL ARTICLE
CHK2 stability is regulated by the E3 ubiquitin ligase SIAH2
C García-Limones1, M Lara-Chica1, C Jiménez-Jiménez, M Pérez, P Moreno, E Muñoz and MA Calzado
The serine threonine checkpoint kinase 2 (CHK2) is a critical protein involved in the DNA damage-response pathway, which is
activated by phosphorylation inducing cellular response such as DNA repair, cell-cycle regulation or apoptosis. Although CHK2
activation mechanisms have been amply described, very little is known about degradation control processes. In the present study,
we identify the ubiquitin E3 ligase SIAH2 as an interaction partner of CHK2, which mediates its ubiquitination and proteasomal
degradation. CHK2 degradation is independent of both its activation and its kinase activity, but also of the phosphorylation in S456.
We show that SIAH2-deﬁcient cells present CHK2 accumulation together with lower ubiquitination levels. Accordingly, SIAH2
depletion by siRNA increases CHK2 levels. In response to DNA damage induced by etoposide, interaction between both proteins is
disrupted, thus avoiding CHK2 degradation and promoting its stabilization. We also found that CHK2 phosphorylates SIAH2 at three
residues (Thr26, Ser28 and Thr119), modifying its ability to regulate certain substrates. Cellular arrest in the G2/M phase induced by
DNA damage is reverted by SIAH2 expression through the control of CHK2 levels. We observed that hypoxia decreases CHK2 levels
in parallel to SIAH2 induction. Similarly, we provide evidence suggesting that resistance to apoptosis induced by genotoxic agents
in cells subjected to hypoxia could be partly explained by the mutual regulation between both proteins. These results indicate that
SIAH2 regulates CHK2 basal turnover, with important consequences on cell-cycle control and on the ability of hypoxia to alter the
DNA damage-response pathway in cancer cells.
Oncogene advance online publication, 11 January 2016; doi:10.1038/onc.2015.495
INTRODUCTION
The serine threonine kinase CHK2 (checkpoint kinase 2) is a highly
conserved protein critical in the DNA damage-response (DDR)
signaling pathway.1,2 Human CHK2 presents three different
domains: an N-terminal region called SQ/TQ cluster domain
(SCD), a forkhead-associated (FHA) domain and a canonical kinase
domain in the C-terminal.3–5 In response to DNA damage, mainly
to double-strand breaks, CHK2 is phosphorylated in threonine 68
by ataxia telangiectasia mutated, which induces its dimerization
and activation.2,6,7
CHK2 regulates several proteins involved in different steps of
the DDR, such as DNA repair, cell-cycle regulation, apoptosis and
p53 signaling.8 To date, 24 substrate proteins of this kinase have
been described in human cells, among which BRCA1, CDC25C,
HDMX, PML and E2F1 are included.2,9–13 CHK2 presents the
ability to regulate p53 activity, either directly through Ser20
phosphorylation,14 or by indirectly phosphorylating other
proteins.9,15
Although CHK2 activation control mechanisms have been
widely described,16,17 very little is known about its inactivation
and degradation processes. Serine/threonine protein phosphatase
2A (PP2A),18 protein phosphatase 1D (WIP1)19 and serine/
threonine protein phosphatase 1 (PP1)20 have been characterized
as responsible to inactivate CHK2. Likewise, during the last decade
several evidences have suggested that ubiquitination is an
important control process in CHK2 turnover.21 Even though two
recent studies have identiﬁed E3 ubiquitin ligase RING ﬁnger
protein 8 (RNF8) in humans22 and p53-induced RING-H2 protein
(PIRH2) in mice23 as regulators of CHK2 through ubiquitination,
the mechanisms required to maintain the steady levels remain
poorly understood.
The E3 ubiquitin ligase SIAH2 (seven in absentia homolog 2)
belongs to the RING (Really Interesting New Gene) ﬁnger E3
ubiquitin ligases.24,25 In humans, two subunits (SIAH1 and SIAH2)
have been described, which present similar and redundant
functions.26,27 SIAH2 is responsible for ubiquitination and proteo-
somal degradation of speciﬁc substrates, either through direct
interaction or through binding to adapter proteins.28–31 SIAH2
controls the expression of substrates involved in important
signaling pathways like PML, HDAC3, TRAF2, β-catenin, HIPK2 and
DYRK2.28,30,32–34 However, its role on the regulation of hypoxia
response stands out, mainly due to its ability to alter the
expression of hypoxia inducible transcription factor 1-alpha
(HIF-1α), which occurs through the degradation of the HIF-1α
prolyl hydroxylases (PHDs).35–37
SIAH2 expression can be controlled at a transcriptional level by
estrogens, different transcription factors (WNT5a and E2F1) and
small noncoding microRNA (MiR-146b).38–42 Different post-
translational modiﬁcations able to modify SIAH2 activity have
been described, such as their ability to autoubiquitinate and the
phosphorylation mediated by upstream kinases.43 To date, only
three kinases able to phosphorylate SIAH2, modifying its activity,
have been described: p38 MAPK,44 and two members of the dual-
speciﬁcity tyrosine-regulated kinase (DYRK) family, HIPK2 and
DYRK2.28,34
Here we describe that SIAH2 interacts with CHK2 and
mediates its ubiquitination and proteasomal degradation.
Both proteins colocalize at the nucleus level and regulate
mutually, and SIAH2 deﬁciency results in higher CHK2 levels.
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In response to DNA damage, interaction between both proteins
is disrupted, thus promoting CHK2 stabilization. Moreover,
we also prove the ability of CHK2 to phosphorylate SIAH2
in at least three residues, modifying its activity on certain
substrates. In summary, we show the ability of SIAH2 to regulate
CHK2 by ubiquitination, which represents a novel regulation
mechanism of the expression and function for this relevant
kinase.
RESULTS
SIAH2 interacts and colocalizes with CHK2
In order to investigate the mechanisms responsible for maintain-
ing the steady levels of CHK2, we tested a set of different E3
ligases for their ability to interact with CHK2 (data not shown). As
SIAH2 showed positive results in our screening, we decided to
focus on this protein in detail. We ﬁrst coexpressed Flag-CHK2
alone or in the presence of hemagglutinin epitope (HA)-tagged
SIAH2 in HEK-293T cells, and performed coimmunoprecipitation
assays. Flag-CHK2 coimmunoprecipitated efﬁciently with HA-
SIAH2 (Figure 1a). Similar results were obtained the other way
round (Figure 1b). Similarly, immunoprecipitation of endogenous
CHK2 pulled down SIAH2 (Figure 1c).
Then, we analyzed the subcellular localization of both proteins
and the effect of DNA damage. CHK2 and SIAH2 proteins mainly
colocalize in the nucleus and no changes were observed in the
cells stimulated with ETP (Figure 1d). Coimmunoprecipitation
experiments showed that the interaction between these two
proteins was markedly reduced under ETP (Figure 1e) and cisplatin
stimulation and, to a lesser extent in response to 5-ﬂuorouracil
(Supplementary Figure S1). All these data support the existence of
a CHK2-SIAH2 complex, which can be partially disrupted in
response to DNA damage.
CHK2 shows a direct interaction with SIAH2
To study whether CHK2 and SIAH2 directly interact and to
characterize the responsible domains, we performed GST-
pulldown assays. Flag-CHK2 was brought down by full-length
SIAH2 and also by two deletion mutants (Figure 2a). Similarly,
Flag-SIAH2 was captured by full-length CHK2 and, to a lesser
extent, by FHA or SCD domain-deleted mutants (Figure 2b). To
identify the sites of direct interaction, we performed a peptide
array experiment (Figure 2c). Detection of the bound material by
antibodies showed that CHK2 binds four distinct domains of
SIAH2. Likewise, SIAH2 showed interactions with two distinct sites
of CHK2 (Supplementary Figure S2A). Then, we compared the
interaction between SIAH2 and full-length CHK2 with FHA or SCD
domain-deleted mutants. As shown in Supplementary Figure S2B,
and in agreement with the results obtained in the GST-pulldown
assays, FHA or SCD domain-deleted mutants were captured to a
lesser degree than full-length CHK2 by Flag-SIAH2. Lastly, we
decided to compare the interaction between SIAH2 and CHK2 wild
type (wt) or CHK2 kinase dead mutant. These experiments
revealed that the loss of CHK2 kinase activity does not
affect the ability to interact with SIAH2 (Figure 2d). All these
results clearly show a direct physical interaction of CHK2 and
SIAH2, suggesting the existence of more than one domain
responsible for binding in both proteins. Similarly, these data
indicate that SIAH2 interacts with CHK2 monomeric and
dimeric forms.
SIAH2 mediates CHK2 ubiquitination and proteosomal
degradation
Based on the ability of SIAH2 to lead the ubiquitination and
proteosomal degradation of many of its interaction partners,
we analyzed whether SIAH2 can degrade CHK2 through an
ubiquitin/proteasome-dependent process. We coexpressed CHK2
with increasing amounts of SIAH2 or the ligase-deﬁcient SIAH2
point mutant (SIAH2 RM). Expression of SIAH2 resulted in a
dose-dependent decrease in CHK2 protein levels in HEK-293T cells
(Figure 3a). Similar results were obtained in MOR and A549 cells
(Supplementary Figure S3A). By contrast, CHK2 levels were not
altered in the presence of the SIAH2 RM. A comparative assay with
SIAH1 showed that SIAH2 is the only member of the human family
able to induce CHK2 degradation (Supplementary Figure S3B).
Then, we examined this effect in the presence or absence of the
proteasome inhibitor MG-132. The addition of this inhibitor
stabilized SIAH2 and signiﬁcantly prevented CHK2 degradation
(Figure 3b).
Next, we decided to analyze the impact of SIAH2 expression at
different levels on the endogenous CHK2. Increasing amounts of
SIAH2 revealed a dose-dependent decrease in CHK2 protein
levels without affecting mRNA expression (Figure 3c). Then we
analyzed the effect of SIAH2 inhibition by siRNA and, based on
the previous results by which DNA damage partially disrupted
SIAH2–CHK2 interaction, also the effect of ETP stimulation. SIAH2
depletion increases CHK2 levels (Figure 3d) as well as its half-life
(Supplementary Figure S4A), indicating that CHK2 basal
levels can be regulated by this E3 ligase. In addition, ETP
stimulation increased CHK2 stability as well as its half-life
(Supplementary Figure S4A), which were not affected by SIAH2
inhibition. These changes were accompanied by an increase in
CDC25C-Ser216 phosphorylation. Taken together, these results
suggest that SIAH2 regulates CHK2 turnover through a mechan-
ism occurring at the protein level, affecting its stability and
activity.
We next examined the effect of SIAH2 on CHK2 ubiquitination
in vivo and in vitro. We coexpressed His-Ubiquitin and HA-CHK2
with or without different concentrations of SIAH2 in the presence
of MG-132, and analyzed the ubiquitination status of CHK2. As
shown in Figure 3e, CHK2 polyubiquitination became more
evident in the presence of increasing concentrations of SIAH2.
By contrast, CHK2 polyubiquitination was inhibited in the
presence of the SIAH2 RM (Supplementary Figure S3C). Then, we
examined the effect of SIAH2 deﬁciency on the basal level of
CHK2 polyubiquitination, comparing control mouse embryonic
ﬁbroblasts (MEFs) to Siah1a− /−/Siah2− /− MEF cells. Ubiquitination
levels of CHK2 were signiﬁcantly lower in the knockout MEFs
lacking Siah1a/2 (Figure 3f). Finally, we analyzed SIAH2 ability to
directly ubiquitylate CHK2 through an in vitro ubiquitination assay.
Polyubiquitination of CHK2 was observed only in the presence of
SIAH2 (Supplementary Figure S4B).
CHK2 phosphorylation is a relevant mechanism for the control
of its activity and stability. After DNA damage, T68 phosphoryla-
tion leads to conformational changes that induce dimerization
and full activation.45,46 Similarly, S456 phosphorylation is critical
for the stability control by ubiquitination.23,47,48 We decided to
evaluate the effect of SIAH2 on CHK2 wt compared with CHK2
S456A and T68A mutants. As shown in Supplementary Figures
S3D and S3E, both mutants were degraded in a similar way to
CHK2 wt, indicating that the phosphorylation status of these
residues is not relevant for the degradation mediated by SIAH2.
Moreover, we compared the interaction between SIAH2 and
CHK2 wt in the presence or absence of ataxia telangiectasia
mutated (ATM) and ATM and Rad3-related (ATR) inhibitor caffeine,
or CHK2 S19A and T68A mutants. Coimmunoprecipitation
experiments revealed that CHK2 phosphorylation status, at least
in these important residues, is not relevant for the association with
SIAH2 (Supplementary Figure S3F). In the same sense, we
evaluated the capacity of SIAH2 to degrade FHA or SCD
domain-deleted mutants (Supplementary Figure S3G). Although
FHA domain-deleted mutant was partially degraded, the expres-
sion of the SCD domain-deleted mutant was not affected. Finally,
we decided to study the effect of DNA damage on CHK2
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Figure 1. CHK2 interacts and colocalizes with SIAH2. (a) HEK-293T cells were transfected with expression plasmids encoding HA-tagged SIAH2
and Flag-CHK2 as indicated, and after 36 h the proteasome inhibitor MG-132 (10 μM) was added for another 12 h to avoid SIAH2
autodegradation. Cells were lysed and subjected to immunoprecipitation (IP) using anti-HA antibody. After elution, Flag-CHK2 protein was
detected by western blotting. A small fraction (5%) of the lysate was tested for the occurrence of the indicated proteins by immunoblot
(INPUT). The positions and molecular weights (in kDa) are indicated. We show a representative blot of three independent experiments. (b) The
experimental settings were similar to (a) with the exception that the inmunoprecipitation was performed using anti-Flag antibody for CHK2.
We show a representative blot of three independent experiments. (c) HeLa cells were lysed and a fraction subjected to IP with anti-SIAH2
antibody or Ig control. The precipitates were subjected to western blot analysis with anti-CHK2 or anti-SIAH2 antibodies. We show a
representative blot of three independent experiments. (d) U2OS cells were transfected with Flag-SIAH2 RM (RING Mutant) and CHK2-GFP and
analyzed for the localization of both proteins by immunoﬂuorescence. Nuclear DNA was stained with DAPI. Overlapping localization in
merged pictures is shown in yellow. We show a representative picture. Correlation analysis revealed a high degree of colocalization with a
value of 0.59± 0.06 for Pearson’s coefﬁcient. No signiﬁcant changes were observed in the cells stimulated with ETP (0.61± 0.07). (e) HEK-293T
cells were transfected with the indicated plasmids, and after 36 h stimulated with etoposide (ETP) 10 μM as indicated and MG-132 for another
12 h. Cells were lysed, subjected to immunoprecipitation using anti-HA antibody, and the different proteins detected by western blotting.
A small fraction (5%) of the lysate was tested by immunoblot for the occurrence of the indicated proteins (INPUT). We show a representative
blot of four independent experiments.
SIAH2 regulates CHK2 protein turnover
C García-Limones et al
3
© 2016 Macmillan Publishers Limited Oncogene (2016) 1 – 13
Figure 2. CHK2 shows direct interaction with SIAH2. (a) HEK-293T cells were transfected to express Flag-CHK2, lysed and incubated with
GST-SIAH2 or deleted versions. After immunoprecipitation, CHK2 protein was detected by western blotting with anti-Flag antibody. The lower
part shows the Coomassie-stained input material and a schematic representation of SIAH2-WT and its mutants. We show a representative blot
of three independent experiments. (b) The experimental settings were similar to (a) with the exception that HEK-293T cells were transfected
to express Flag-SIAH2, lysed and incubated with GST-CHK2 or deleted versions. We show a representative blot of three independent
experiments. (c) Schematic representations of SIAH2 and CHK2 with the regions responsible for interaction. Recombinant GST-CHK2 or
GST-SIAH2 proteins (or GST control protein) were incubated with a peptide array library covering the complete sequence of SIAH2 or CHK2,
respectively, and bound proteins were revealed by immunoblot. CHK2 binds to four distinct domains of SIAH2, while SIAH2 interacts with two
domains in the lower part of CHK2. Sequences of peptides interacting with CHK2 and SIAH2 are shown in Supplementary Figure S2A. We
show a representative blot of two independent experiments. (d) HEK-293T cells were transfected with expression plasmids indicated,
stimulated with MG-132 during 12 h, lysed and subjected to immunoprecipitation (IP) using anti-Flag antibody. Protein expression was
detected by western blotting with the indicated antibodies. A fraction of the lysate was used to test the expression of the indicated proteins
(INPUT). We show a representative blot of three independent experiments.
SIAH2 regulates CHK2 protein turnover
C García-Limones et al
4
Oncogene (2016) 1 – 13 © 2016 Macmillan Publishers Limited
degradation by SIAH2. ETP stimulation prevented CHK2 poly-
ubiquitination (Supplementary Figure S4C), degradation by SIAH2
(Figure 3g) and increased its half-life (Supplementary Figure S4A).
Similar results were obtained after stimulation with cisplatin and
5-ﬂuorouracil (Supplementary Figure S4D). Collectively, these data
show that SIAH2 stimulates basal CHK2 polyubiquitination,
thereby identifying CHK2 as a substrate for SIAH2-mediated
ubiquitination and proteasomal degradation.
CHK2 phosphorylates SIAH2 in at least three residues in vivo
and in vitro
As we showed in previous works,28,34 some kinase substrates of
SIAH2 have the ability to phosphorylate this E3 ligase. Therefore,
we tested the capacity of CHK2 to phosphorylate SIAH2. CHK2
overexpression resulted in the presence of slower migrating SIAH2
bands, an effect not observed with CHK2 kinase dead mutant (KD)
(Figure 4a). SIAH2 phosphorylation was analyzed with a speciﬁc
phospho-SIAH2 antibody for Ser28.28 To conﬁrm that the
upshifted SIAH2 bands were phosphorylated forms, we incubated
cell extracts with λ-phosphatase. Treatment transformed the
slower electrophoretic mobility bands into the faster migrating
bands, and SIAH2 phosphorylation disappeared (Figure 4b). These
results indicate that the upshifted SIAH2 bands observed after
CHK2 wild-type overexpression represent hyperphosphorylated
forms.
To examine the capacity of CHK2 to directly phosphorylate
SIAH2, we performed an in vitro kinase assay. The presence of
GST-CHK2 showed the occurrence of an upper band of GST-SIAH2
detected with a speciﬁc phospho-SIAH2 antibody (Figure 4c),
which disappeared after λ-phosphatase treatment (Supplementary
Figure S5). Next, we evaluated the CHK2 ability to phosphorylate
endogenous SIAH2 by comparing phospho-SIAH2 endogenous
levels of control cells to the cells where endogenous CHK2 was
knock down by siRNA (Figure 4d). CHK2 inhibition caused a
signiﬁcant reduction of endogenous SIAH2-Ser28 phosphoryla-
tion. Taken together, these results clearly indicate that CHK2 can
directly phosphorylate SIAH2.
To identify the SIAH2 sites phosphorylated by CHK2, we used
four different phospho-speciﬁc antibodies (Thr26, Ser28, Ser68
and Thr119) previously described.34 SIAH2 or point mutants of the
phosphorylated amino acids to alanine were expressed either
alone or together with CHK2, followed by detection of single-site
phosphorylation (Figure 4e). CHK2 expression caused phosphor-
ylation in three different sites (Thr26, Ser28 and Ser68), but we did
not observe any signiﬁcant changes in Thr119. Ser28 mutation
precluded phosphorylation at Thr26, probably due to the fact that
these sites are very close and in the same epitope. Once again, we
examined the effect of ETP stimulation on SIAH2 phosphorylation
by CHK2. As shown in Figure 4f and coherent with the previous
results, stimulation with ETP decreased substantially SIAH2
phosphorylation levels mediated by CHK2. Overall, these results
clearly indicate that CHK2 directly phosphorylates SIAH2 at a
minimum of three residues.
Effect of SIAH2 phosphorylation on CHK2 turnover via
ubiquitination and proteosomal degradation
Does SIAH2 phosphorylation by CHK2 control the degradation of
this kinase through the ubiquitin/proteasome system? To address
this issue, we transfected HEK-293T cells with Flag-CHK2 or
Flag-CHK2 KD with increasing amounts of Flag-SIAH2. CHK2
degradation by SIAH2 was independent of the presence of its
kinase activity (Figure 5a). Next, we compared the capacity of the
phosphorylation (SIAH2-3A) and the phosphomimic (SIAH2-3D)
mutants in the residues phosphorylated by CHK2 to degrade this
kinase. Cells were transfected with Flag-CHK2 together with Flag-
SIAH2-WT, Flag-SIAH2-3A or Flag-SIAH2-3D, using Flag-SIAH2 RM
as a negative control. As shown in Figure 5b, CHK2 was degraded
to a similar way in the three cases. These results support the
hypothesis that the phosphorylation state of SIAH2 does not alter
its capacity to degrade CHK2.
Others and we have revealed how SIAH2 phosphorylation
affects its activity on certain substrates. Although the former
results indicated that this is not the case for CHK2, we decided to
analyze the effect on other substrates as prolyl hydroxylase 3
(PHD3). SIAH2 regulates hypoxia-inducible factor 1-alpha (HIF-1α)
expression mostly via PHD3 inhibition.35 Cells were transfected
with HA-PHD3, together with different SIAH2 variants in the
presence or absence of Flag-CHK2, and a luciferase construct
controlled by the HIF-1-dependent erythropoietin promoter
(Epo-Luc). SIAH2 produced an important reduction in PHD3
expression, which was reﬂected in a signiﬁcant induction of
HIF-dependent Epo-Luc promoter activity. SIAH2-3A mutant
showed a reduced capacity to degrade PHD3, reﬂected in a lower
response to the Epo-Luc promoter. On the contrary, the
phosphomimetic SIAH2-3D mutant showed a strongly increased
ability to degrade PHD3 and increase the Epo-Luc promoter
response (Figure 5c). Coexpression of CHK2 strongly diminished
PHD3 inhibition by SIAH2 and showed a signiﬁcant reduction in
the Epo-Luc promoter response. This effect, compared with the
result obtained in response to the phosphomimetic SIAH2-3D
mutant, suggests the possible CHK2 ability to phosphorylate
SIAH2 in more residues with different consequences on its activity.
Altogether, these experiments demonstrate that the SIAH2
phosphorylation mediated by CHK2 can regulate its capacity to
degrade PHD3.
We subsequently investigated the effects of SIAH2 phosphor-
ylation state in response to CHK2 on its capacity to degrade other
two relevant SIAH2 substrates as DYRK2 and HIPK2. HEK-293T cells
were transfected with kinase inactive mutants Flag-DYRK2 KD
(Figure 5d) or Flag-HIPK2 KD (Supplementary Figure S6A) in order
not to interfere with SIAH2 phosphorylation state, together with
SIAH2 in the presence or absence of full-length CHK2, FHA or SCD
domain-deleted mutants. In agreement with the PHD3 results, the
presence of CHK2 signiﬁcantly reduced HIPK2 and DYRK2
degradation. By contrast, FHA or SCD domain-deleted mutants,
which lack the ability to phosphorylate SIAH2 (Supplementary
Figure S6B), did not change the levels of both kinases. Altogether
these data suggest that SIAH2 phosphorylation mediated by CHK2
does not affect its capacity to degrade this kinase, but modulates
its ability to regulate other substrates such as PHD3, DYRK2
and HIPK2.
Effect of SIAH2 on CHK2 capacity to regulate cell-cycle arrest or
apoptosis in response to DNA damage
CHK2 kinase has a relevant role in the DDR through cell-cycle
checkpoint regulation.2 Therefore, we tested the ability of SIAH2
to affect cell-cycle checkpoint activation in response to DNA
damage. HEK-293T cells were transfected or not with SIAH2 and
treated or not with ETP during 12 h. This time was taken to
observe the direct effect on the cell-cycle arrest, which was
analyzed together with the expression of CHK2, CDC25C and
SIAH2 proteins. As depicted in Figure 6a, SIAH2 expression
resulted in a clear reversion of the cellular arrest in the G2/M
phase induced by the stimulation with ETP, presenting an
inhibition of total and phosphorylated CHK2 (Thr68 and Ser516)
and a reduction in phospho-CDC25C-Ser216 protein (CHK2
substrate).
We then investigated whether SIAH2 contributes to the
apoptosis induced by DNA damage and the CHK2 role on this
effect. HeLa cells were transfected with the indicated plasmids
and stimulated with ETP. As shown in Figure 6b, the apoptosis
percentage induced by stimulation with ETP was reduced in
response to SIAH2 expression. In parallel, a signiﬁcant reduction in
the CHK2 expression was observed. Restoration of CHK2 protein
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expression to its endogenous levels was associated with a
signiﬁcant recovery of apoptosis. Cell-cycle phase analysis was
performed in parallel (Supplementary Figure S7A). In addition, we
observed that SIAH2 expression increases cell viability in response
to cytotoxic drugs (5-FU or Oxaliplatin) in HEK-293T (Figure 6c)
and HeLa cells (Supplementary Figure S7B). Overall, these
results indicate the SIAH2 ability to partially regulate the CHK2
capacity to control cell-cycle arrest or apoptosis in response to
DNA damage.
Finally, we decided to study the functional consequences of
CHK2-SIAH2 modulation in the context of hypoxia. SIAH2 is an
essential component of the hypoxia response pathway with
relevant implications on the carcinogenesis control.35,49 Moreover,
one of the causes of hypoxic tumor resistance to treatment is the
hypoxia ability to alter the DDR signaling pathway.50 To test this
hypothesis, HeLa cells were subjected to hypoxia, stimulated with
ETP and the apoptosis compared in control cells and cells where
endogenous SIAH2 was knock down. Hypoxia reduced the
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percentage of apoptosis in response to ETP, increasing SIAH2
levels and signiﬁcantly reducing CHK2 expression. Moreover,
SIAH2 depletion increased CHK2 levels, which was accompanied
by a signiﬁcant recovery of apoptosis (Figure 6d). Similar
experiments were performed in A549 and MOR cells where, again,
hypoxia produced a clear decrease in total and Thr68 CHK2 levels,
thereby affecting its activity on CDC25C. SIAH2 knockdown under
hypoxia conditions produced a signiﬁcant increase in CHK2, which
was also reﬂected in its activity (Supplementary Figures S8A and
S8B). Similar results were obtained in the same cisplatin-resistant
cell lines, thus indicating that this regulation is conserved in at
least these two cell types. Collectively, all these results conclu-
sively show that hypoxia regulates, at least partially, CHK2 stability
and activity depending on SIAH2 expression levels. Similarly, they
suggest that the resistance to apoptosis induced by genotoxic
agents in cells subjected to hypoxia is due, at least in part, to the
alteration of the DDR signaling pathway, which can be explained
as a consequence of CHK2 depletion mediated by the expression
of SIAH2.
DISCUSSION
The ubiquitin–proteasome pathway is critical for the expression
and activity control of proteins implicated in cell-cycle control and
DNA damage response.51,52 CHK2 is a stable protein with a 6-h
half-life whose regulation and degradation mechanisms in the
absence of DNA damage are not completely known.2,53 Although
the phosphorylation levels and the action of several phosphatases
are the most relevant mechanisms to keep CHK2 inactive,18–20
different evidences suggest the role of ubiquitination to control its
stability. Firstly, the capacity of Ub E3 ligase Mdm2 and
acetyltransferase PCAF to increase CHK2 ubiquitination has been
described, but in an independent way to their E3 ligase
activities.48 Similarly, the role of EDD in CHK2 activation has been
reported, although its ability to mediate CHK2 ubiquitination has
not been demonstrated yet.54 Recently, the ability of the E3 ligase
RNF8 in human, and PIRH2 in mice to ubiquitylate and degrade
CHK2 has been characterized.22,23 It should be underlined that,
whereas these two E3 ligases mediate degradation in response to
DNA damage, our results suggest that SIAH2 regulates CHK2 basal
expression.
In the present work we describe the capacity of CHK2 to directly
interact in vivo with SIAH2, mainly colocalizing in the nucleus.
Through different experimental approaches, we prove that SIAH2
mediates CHK2 ubiquitination and proteosomal degradation.
SIAH2 depletion increases CHK2 levels, thereby supporting our
observation that SIAH2-deﬁcient cells show high CHK2 levels.
Phosphorylation in S456, which has been proved to be critical for
CHK2 ubiquitination, is not here relevant for CHK2 degradation.47
Similarly, our results show that SIAH2-mediated CHK2 degradation
is independent of both phosphorylation in T68 and its kinase
activity. Likewise, DNA damage alters the interaction between
both proteins, thus decreasing SIAH2-mediated CHK2 levels and
not affecting the endogenous levels of CHK2 T68 or S516. These
results suggest that SIAH2 interacts and regulates a pool of CHK2
in the absence of stimuli. In response to DNA damage, a CHK2
fraction would split from SIAH2, thus avoiding its degradation and
allowing its stabilization. Although the exact mechanism under-
lying the separation of SIAH2 from CHK2 after DNA damage is
unknown, it seems reasonable to think that it could be the result
of post-transductional modiﬁcations suffered by any of the two
proteins in response to this stimulus. The absence of a complete
dissociation of both proteins in response to DNA damage
observed in our results could explain the existence of different
CHK2 fractions controlled by SIAH2 contributing to the cell-cycle
control (Figure 7).
The regulation of ubiquitin ligases activity is critical for the
control of its substrates. Different control mechanisms have been
described for SIAH family, among which the role of phosphoryla-
tion stands out.42 Others and we have reported that SIAH2
phosphorylation affects its activity, and three kinases with SIAH2
as substrate have been described so far.28,34,44 In this work we also
highlight CHK2 capacity to phosphorylate SIAH2 in at least three
residues, not affecting its activity on this kinase, but decreasing its
ability to degrade other substrates. These results are consistent
with previous reports describing how SIAH2 phosphorylation
modulates its activity speciﬁcally on certain substrates.34,55,56
Similarly, our results show how ETP stimulation signiﬁcantly
reduces CHK2-mediated SIAH2 phosphorylation, in agreement
with the loss of interaction between these two proteins. As a
consequence, the activity of SIAH2 on some of its substrates in
response to DNA damage would be modiﬁed. The changes
observed in some SIAH2 substrates in response to DNA damage
such as DYRK2 are in accord with this hypothesis.57,58
From the functional point of view, CHK2 plays a relevant role in
the cell-cycle control in response to DNA damage, inhibiting
CDC25C phosphatase through Ser216 phosphorylation and
avoiding mitosis.2,59 Our results demonstrate how SIAH2 expres-
sion resulted in a clear reversion of cellular arrest induced by ETP
stimulation. Besides, we demonstrate that the loss of SIAH2-
mediated CHK2 partially prevented ETP-induced apoptosis on
HeLa cells, which was recovered by returning CHK2 protein
expression to endogenous levels. These data prove that SIAH2
Figure 3. SIAH2 mediates ubiquitin/proteasomal degradation of CHK2. (a) HEK-293T cells were transfected to express CHK2 and the levels
were evaluated in response to increasing concentrations of SIAH2 wild type or SIAH2 RING mutant by western blotting. We show a
representative blot of three independent experiments. (b) Cells were transfected with the indicated plasmids to express CHK2 and increasing
concentrations of SIAH2 in the presence or absence of MG-132. Cells were lysed and protein expression analyzed by immunoblot. We show a
representative blot of three independent experiments. (c) HEK-293T cells were transfected to express increasing amounts of SIAH2, harvested
and lysed. One fraction was used to analyze the endogenous CHK2 protein levels while another aliquot was used to analyze the CHK2 mRNA
levels by quantitative PCR. Data are mean± s.d. of n= 3. We show a representative blot of three independent experiments. Primer sequences
are available upon request. (d) HEK-293T cells were transfected with SIAH2 or scrambled (control) siRNAs, after 4 days stimulated with
etoposide (10 μM) during 24 h as indicated, lysed and protein expression analyzed by immunoblot. We show a representative blot of three
independent experiments. (e) HEK-293T cells were transfected with expression plasmids encoding HA-tagged CHK2, Flag-tagged SIAH2 and
His-tagged ubiquitin. After 36 h cells were incubated in the presence of MG-132 (10 μM) during 12 h and lysed under denaturing conditions.
His-tagged ubiquitin was puriﬁed with Ni-NTA agarose columns and ubiquitinated CHK2 was analyzed by western blotting. A fraction was
tested for the occurrence of the indicated proteins (INPUT). We show a representative blot of three independent experiments. (f) Wild type
and Siah1a− /−/Siah2− /− MEF cells were stimulated or not with MG-132 during 12 h, lysed and subjected to immunoprecipitation using anti-
CHK2 antibody. The precipitates were subjected to western blot analysis with anti-CHK2 or anti-Ub antibodies. A small fraction of the lysate
was tested for the occurrence of CHK2 (INPUT). We show a representative blot of three independent experiments. (g) HEK-293T cells were
transfected or not to express SIAH2, and 24 h post-transfection stimulated with etoposide (10 μM) during 24 h as indicated. Cells were lysed
and protein expression was analyzed by immunoblot with the indicated antibodies. We show a representative blot of three independent
experiments.
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Figure 4. CHK2 phosphorylates SIAH2 in vivo and in vitro. (a) HEK-293T cells were transfected to express Flag-SIAH2 and increasing amounts of
Flag-CHK2 wild type or Flag-CHK2 kinase dead mutant (KD), and after 36 h treated for 12 h with the proteasome inhibitor MG-132 (10 μM). Cell
lysates were analyzed by immunoblotting with the indicated antibodies. SIAH2 phosphorylation was seen by the upshifted band and also by
the use of a speciﬁc antibody recognizing phosphorylated Ser28 of SIAH2. We show a representative blot of three independent experiments.
(b) HEK-293T cells were transfected with the indicated plasmids and treated with MG-132 for 12 h. Cells were lysed in phosphatase inhibitor-
free buffer in the absence or presence of λ-phosphatase. Electrophoretic mobility was determined by immunoblotting and in parallel SIAH2
phosphorylation was analyzed with phospho-speciﬁc antibody for Ser28 of SIAH2. We show a representative blot of three independent
experiments. (c) In vitro kinase assay was performed with active CHK2 recombinant protein and puriﬁed GST-SIAH2. Phosphorylation was
determined with phospho-speciﬁc antibody for Ser28 of SIAH2, while protein levels were visualized by Coomassie staining (lower).
(d) HEK-293T cells were transfected with CHK2 or scrambled (control) siRNAs, lysed after 4 days of culture and CHK2 or SIAH2 phosphorylation
analyzed by western blot. We show a representative blot of three independent experiments. (e) HEK-293T cells were cotransfected with Flag-
SIAH2 or the indicated SIAH2 point mutants either alone or along with CHK2 and treated with MG-132 for 12 h. Electrophoretic mobility was
determined by western blotting and in parallel SIAH2 phosphorylation was analyzed with phospho-speciﬁc antibodies for the residues
indicated. We show a representative blot of three independent experiments. (f) Cells were transfected to express HA-SIAH2 in the presence or
absence of Flag-CHK2. Twenty-four hours post-transfection cells were stimulated with etoposide (6 μM) during 24 h, lysed and protein
expression was analyzed by immunoblot with the indicated antibodies. SIAH2 phosphorylation was analyzed with phospho-speciﬁc antibody
for Ser28. We show a representative blot of three independent experiments.
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expression affects cell-cycle activation checkpoints through the
control of CHK2 levels.
Finally, many studies support the concept that hypoxia is
directly implicated in tumor progression and metastasis, mediat-
ing apoptosis resistance and reducing the ability to repair
DNA.50,60 Different works have reported how intratumoral hypoxia
signiﬁcantly modiﬁes the action of some drugs and promotes
metastasis.60,61 Similarly, cells subjected to hypoxia present a
lower capacity to repair DNA and, as a consequence, they become
more resistant to chemotherapy.62,63 Different clinical trials that
attempted to diminish tumor hypoxia have signiﬁcantly improved
cell sensibility to radiotherapy and chemotherapy, which resulted
in a higher rate of survival.64 In general, the concept that hypoxia
increases cell resistance to apoptosis through different mechan-
isms is consistent with our results. SIAH2 has the capacity to
regulate HIF-1α levels, and thus the physiological response to
hypoxia.35 We observed that hypoxia decreases CHK2 levels,
parallel to an increase of both SIAH2 and cell resistance to
apoptosis induced by ETP. We have also observed how SIAH2
expression increases cell viability in response to cytotoxic drugs
such as 5-FU or Oxaliplatin. These data are equally supported, at
least partially, by previous results which also showed lower CHK2
levels under hypoxia in HeLa and MCF-7 cells.65 Altogether, this
ﬁnding suggests a new action mechanism by which hypoxia may
alter the DDR pathway via SIAH2–CHK2 modulation.
In summary, our results indicate that E3 ubiquitin ligase SIAH2
regulates CHK2 basal turnover. Additionally, CHK2 presents the
ability to phosphorylate SIAH2, affecting its activity on certain
substrates. In response to DNA damage, the interaction between
both proteins is altered, which favors CHK2 stabilization. We
propose that this new CHK2 regulation mechanism has an
inﬂuence on cell-cycle control and on the ability of hypoxia to
alter the DDR pathway in cancer cells. Further studies of the
relationship of these two proteins in tumors are needed to
support this hypothesis.
MATERIALS AND METHODS
Cell cultures and reagents
HEK-293T, HeLa, U2OS, A549 (wt/CPR), control MEFs and Siah1a− /−/Siah2− /−
MEF cells were maintained in Dulbecco's modiﬁed Eagle's medium,
MOR (wt/CPR) in RPMI, both supplemented with 10% fetal calf serum,
Figure 5. Regulation of SIAH2 activity by CHK2. (a) HEK-293T cells were transfected to express Flag-CHK2 or Flag-CHK2 KD (Kinase mutant)
with increasing amounts of SIAH2, lysed and protein expression was analyzed by immunoblot with the indicated antibodies. We show a
representative blot of four independent experiments. (b) Cells were transfected with Flag-CHK2 and the plasmids encoding SIAH2 wild type
and the phosphorylation (SIAH2-3A) and the phosphomimic (SIAH2-3D) mutants in the residues Thr26, Ser28 and Ser68. After 36 h cells were
lysed and the stability of CHK2 was revealed by immunoblotting. We show a representative blot of three independent experiments.
(c) HEK-293T cells were transfected with the indicated plasmids together with a luciferase construct controlled by the HIF-1-dependent
erythropoietin promoter (Epo-Luc). After 36 h, cells were lysed and further analyzed for the indicated proteins by immunoblots (upper panel)
or for luciferase expression (lower panel). Data are mean± s.d. of n= 3 experiments. ***Po0.001. We show a representative blot of three
independent experiments. (d) HEK-293T cells were transfected with the indicated plasmids, and after 36 h lysed and protein expression
evaluated by immunoblot with the indicated antibodies. We show a representative blot of three independent experiments.
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2 mM L-glutamine and 1% (v/v) penicillin/streptomycin at 37 °C in a
humidiﬁed atmosphere containing 5% CO2. Cell lines are routinely tested
to be free of mycoplasma and cross contamination. Cell lines validation
was performed by a multiplex PCR with Geneprint10 System (Promega,
Madison, WI, USA). HEK-293T, HeLa, U2OS and control MEFs cells were
obtained from ATCC (LGC Standards, Teddington, Middlesex, UK). A549 wt/
CPR cells and Epo-Luc plasmid were a gift from Dr M L Schmitz (University
of Giessen, Germany). MOR wt/CPR were from Sigma-Aldrich (St Louis, MO,
SIAH2 regulates CHK2 protein turnover
C García-Limones et al
10
Oncogene (2016) 1 – 13 © 2016 Macmillan Publishers Limited
USA). Siah1a− /−/Siah2− /− MEF cells were obtained from Dr David Bowtell
and Dr Andreas Möller. MG-132 was from Enzo Life Science (Lausen,
Switzerland), and the rest of the reagents were from Sigma-Aldrich.
Scramble control oligonucleotide siRNA non-targeting pool (D-001810-10-
20) and the siGENOME SMARTpool against SIAH2 (M-006561-02) and ON-
TARGET plus SMARTpool against CHK2 (L-003256-00) were purchased from
Dharmacon (Waltham, MA, USA). E1, E2-UbcH5c and ubiquitin human
recombinant proteins were purchased from Abcam (Cambrigde, UK).
Transfection and plasmids
Transient transfections, SIAH2 plasmids and His-Ubiquitin were previously
described.28,34 Flag-CHK2, KD and T68A, Myc-CHK2, KD were a gift from
Dr H Piwnica-Worms (Washington University School of Medicine, St Louis,
MO, USA). GST-CHK2 plasmid was a gift from Dr Stephen J Elledge (Harvard
Medical School, Boston, MA, USA). HA-CHK2, KD, GST-CHK2-ΔSCD and
ΔFHA plasmids were kindly provided by Dr David F Stern (Yale University
School of Medicine, New Haven, CT, USA). HA-CHK2 S456A was provided
by Dr Carol Prives (Department of Biological Sciences, Columbia University,
New York, NY, USA). CHK2-GFP was provided by Dr L Zannini (Istituto
Nazionale dei Tumori, Milan, Italy). Myc-CHK2 ΔSCD and ΔFHA were kindly
provided by Dr S-Y Shieh (Institute of Biomedical Science, Taiwan). Flag-
CHK2 S19A was a gift from Dr Domenico Delia (Istituto Nazionale dei
Tumori, Milan, Italy). PHD3 plasmid was a gift from Dr Frank S Lee
(Pennsylvania School of Medicine, Philadelphia, PA, USA).
Cell lysis, western blot, immunoprecipitation analysis,
immunoﬂuorescence and antibodies
Cells lysis, sodium dodecyl sulfate polyacrylamide gel electrophoresis,
immunoblotting, immunoprecipitation, enrichment of His-tagged proteins
and Immunoﬂuorescence were described by us previously.28,34 Mouse
monoclonal antibodies against Flag (M2) and anti-β-actin (AC-74) were
purchased from Sigma-Aldrich, anti-HA epitope (3F10) and anti-myc (9E10)
from Roche Molecular Biochemicals (Mannheim, Germany), anti-p53
phospho Ser46 (2521), anti-ubiquitin (P4D1), anti-CHK2 Thr68 [(C13C1)-
2197], anti-CDC25C Ser216 (9528), anti-CHK2 Ser516 (2669) and anti-p53
Ser20 (9287) from Cell Signaling Technology (Danvers, MA, USA), anti-
SIAH2 (sc-5507) and anti-p53 (sc-126) from Santa Cruz (Santa Cruz, CA,
USA). Anti-phospho-SIAH2 antibodies were previously described.28,34 Alexa
Fluor 647 goat anti-mouse IgG1 (A21235) antibody was from Life
technologies (Carlsbad, CA, USA). Secondary horseradish peroxidase
-coupled antibodies were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA).
Hypoxia, GST-pulldown experiments, in vitro ubiquitination and
phosphorylation, peptide array-binding assays, quantitative
reverse transcriptase–PCR, luciferase reporter and cell viability
assays and ﬂow cytometry analyses
Hypoxia, GST-pulldown experiments, in vitro phosphorylation, peptide
array-binding assays and quantitative reverse transcriptase–PCR,34 in vitro
ubiquination and ﬂow cytometry analyses,66 Luciferase and cell viability
assays67 were performed as described previously.
Figure 6. Functional consequences of CHK2 regulation by SIAH2. (a) HEK-293T cells were transfected with increasing amounts of SIAH2 and
after 12 h stimulated with etoposide (6 μM) during 12 h. A fraction of the cells was used for cell-cycle analysis (left panel) using ﬂow cytometry.
The left panel shows representative cell-cycle distributions. The right panel shows quantitation of percentages of the cells in each phase of the
cell-cycle. Data are mean± s.d. of n= 3 experiments. Another aliquot (lower panel) was lysed and protein expression was analyzed by
immunoblot with the indicated antibodies. We show a representative blot of three independent experiments. (b) HeLa cells were transfected
with the indicated plasmids and 24 h later stimulated with ETP (10 μM) for another 24 h. One aliquot was used for apoptosis analysis
determined by ﬂow cytometry using Annexin V/PI staining (upper panel), while another fraction was lysed and the levels of the indicated
protein analyzed by immunoblot. Data are mean± s.d. of n= 3 experiments. ***Po0.001. (c) HEK-293T cells were transfected or not to express
SIAH2 and 24 h later stimulated as indicated with 5-ﬂuorouracil (5-FU, 0.5 μg/ml) or Oxaliplatin (0.5 μM) during 24 h. Cell viability was measured
by MTT assay. Data are mean± s.d. of n= 3 experiments. *P= 0.01; **P= 0.002; ***Po0.001. (d) HeLa cells were transfected with the indicated
siRNA and 24 h later stimulated with ETP 10 μM for another 24 h. Cells were subjected to hypoxia (1% O2) during 12 h and one fraction used for
apoptosis analysis by Annexin V/PI staining (upper panel), while another fraction was lysed and the levels of the indicated protein were
analyzed by immunoblot. Data are mean± s.d. of n= 3 experiments. ***Po0.001.
Figure 7. Schematic model for the ability of SIAH2 to regulate CHK2 by ubiquitination. Under normal conditions SIAH2 is able to interact and
modulate the basal turnover of CHK2 by ubiquitination and proteasome degradation. Simultaneously, CHK2 is able to phosphorylate SIAH2 in
at least three residues (Thr26, Ser28 and Ser68). The DNA damage response causes alteration in the protein–protein interaction, promoting
CHK2 stabilization and SIAH2 activity modiﬁcation.
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Statistical analysis
Data are expressed as mean± s.d.. Differences were analyzed by Student's
t-test. Statistical analyses were performed using GraphPad Prism version
6.00 (GraphPad, San Diego, CA, USA). Po0.05 was considered signiﬁcant.
Images were analyzed and quantiﬁed using the ImageJ v1.45 software.
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